<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":4245,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (Eurand, Inc. v. Mylan Pharmaceuticals, Inc.), 676 F.3d 1063, 102 U.S.P.Q.2d 1760 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/8aa6afcb6c93e1fd566e4a7344efbc84'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/8aa6afcb6c93e1fd566e4a7344efbc84'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1HF8QG003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HF8QG003">Previous Result: <span>Vega v. Rell, CASE NO. 3:09-cv-737 (VLB)...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1HF8QK003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HF8QK003">Next Result: <span>Thomas v. Astrue, Civil Action No. 11-44...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (Eurand, Inc. v. Mylan Pharmaceuticals, Inc.), 676 F.3d 1063, 102 U.S.P.Q.2d 1760 (Fed. Cir. 2012), Court Opinion'>
In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (Eurand, Inc. v....
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (Eurand, Inc. v. Mylan Pharmaceuticals, Inc.), 676 F.3d 1063, 102 U.S.P.Q.2d 1760 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1HF6KC003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (Eurand, Inc. v. Mylan Pharmaceuticals, Inc.)</div>
<div class='displayCitation'>102 U.S.P.Q.2d 1760</div>
<div class='displayCitation'>2012 BL 92043</div>
<div class='displayCitation'>676 F.3d 1063</div>
<div class='displayCitation'>bna a0d1m7n3v1</div>
<div class='displayCitation'>bna a0d1u3b4z7</div>
<div class='displayCitation'>bna a0d2q1d8n9</div>
<div class='displayCitation'>wkffecase:25939270</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1HF6KC003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (Eurand, Inc. v. Mylan Pharmaceuticals, Inc.), 676 F.3d 1063, 102 U.S.P.Q.2d 1760 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (Eurand, Inc. v. Mylan Pharmaceuticals, Inc.)" />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1HF6KC003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1HF6KC003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1HF6KC003" /><input id="title" name="title" type="hidden" value="In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (Eurand, Inc. v. Mylan Pharmaceuticals, Inc.), 676 F.3d 1063, 102 U.S.P.Q.2d 1760 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="8aa6afcb6c93e1fd566e4a7344efbc84" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1HF6KC003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%38aa%36afcb%36c%39%33e%31fd%35%36%36e%34a%37%33%34%34efbc%38%34%2Fdocument%2FX%31HF%36KC%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/bcite/X1HF6KC003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/bcite/X1HF6KC003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/bcite/X1HF6KC003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/related_content/X1HF6KC003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1699955998723";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">676 F.3d 1063</div>
<div class="cite" data-cite-type="ReporterOfDecisions">102 U.S.P.Q.2d 1760</div>
<div class="cite" data-cite-type="DocketNumber">Nos. 2011-1399, 2011-1409.</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 92043</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
In re CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PATENT
LITIGATION. Eurand, Inc. (Now Known as Aptalis Pharmatech, Inc.),
Cephalon, Inc., and Anesta AG, Plaintiffs-Cross Appellants, v. Mylan
Pharmaceuticals Inc. and Mylan Inc., Defendants-Appellants, and Par
Pharmaceutical, Inc., Defendant-Appellee.
</center></p>
<hr align="center" width="65%">
<p><center>
Nos. 2011-1399, 2011-1409.
</center></p>
<p><center>
April 16, 2012.
<span CLASS="page_no" data-cite="102 uspq 2d 1763" data-cite-type="ReporterOfDecisions" data-cite-pageno="1763" data-primary-citation="102 U.S.P.Q.2d 1760">[**1763]</span> </center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<span>[1]</span> <span>Patentability/Validity &mdash; Obviousness &mdash; References and claims as whole </span> <a href="http://www.bloomberglaw.com/document/1699955998723/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0904" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0904">&#9658;115.0904</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnote_text">
Patents directed to extended-release formulations of skeletal muscle relaxants containing cyclobenzaprine hydrochloride cannot be held obvious based on bioequivalence of pharmacokinetic profiles for extended-release and immediate-release formulations of drug, since obviousness determination also requires consideration of asserted claims' limitation requiring therapeutic effectiveness, and whether it would have been obvious to person of ordinary skill in art that bioequivalent PK value would satisfy that limitation, since cyclobenzaprine lacked known pharmacokinetic/pharmacodynamic relationship at time of invention, and without known PK/PD relationship, skilled artisans could not predict whether any particular PK profile, including bioequivalent one, would produce therapeutically effective formulation, and since there is no evidence that prior art would have taught or suggested therapeutically effective formulation; although it may have been obvious to experiment with use of PK profile for immediate-release formulation when contemplating extended-release formulation, there is no indication that skilled artisan would have had reasonable expectation that such experiment would succeed in being therapeutically effective.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<span>[2]</span> <span>Patentability/Validity &mdash; Obviousness &mdash; Evidence of </span> <a href="http://www.bloomberglaw.com/document/1699955998723/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0906" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0906">&#9658;115.0906</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnote_text">
Evidence proffered in support of obvious-to-try theory is insufficient unless it indicates that possible options skilled artisans would have encountered were &ldquo;finite,&rdquo; &ldquo;small,&rdquo; or &ldquo;easily traversed,&rdquo; and that skilled artisans would have had reason to select route that produced claimed invention; in present case, federal district court erred by relying on interpretation given prior art by infringement defendants&rsquo; expert in concluding that invention of patents for extended-release formulations of skeletal muscle relaxants containing cyclobenzaprine hydrochloride were obvious based on bioequivalence of pharmacokinetic profiles for extended-release and immediate-release formulations of drug, since cyclobenzaprine lacked known pharmacokinetic/pharmacodynamic relationship at time of invention, since nothing in expert's testimony sheds light on why person of ordinary skill in art would have chosen bioequivalent PK profile in absence of known PK/PD relationship, and since absence of such testimony suggests that skilled artisans would not have encountered finite, small, or easily traversed options in developing therapeutically effective, extended-release formulation.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<span>[3]</span> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1699955998723/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Obviousness &mdash; Evidence of </span> <a href="http://www.bloomberglaw.com/document/1699955998723/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0906" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0906">&#9658;115.0906</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court erred by relying on inventor's testimony in concluding that invention of patents for extended-release formulations of skeletal muscle relaxants containing cyclobenzaprine hydrochloride were obvious based on bioequivalence of pharmacokinetic profiles for extended-release and immediate-release formulations of drug, since, in relying on that testimony, district court merely retraced inventor's steps in creating computer models of claimed pharmacokinetic values after reviewing PK data for immediate-release formulation, and such hindsight analysis is inappropriate inasmuch as obviousness must be assessed as of time invention was made, and since inventor's testimony does not support district court's finding that claimed PK values for extended release formulation could be obtained by &ldquo;routine experimentation&rdquo;;
U.S. Food and Drug Administration directive, stating that extended release dosage for drug should have same PK values as already approved immediate release dosage form, does not support obviousness finding, since cyclobenzaprine lacked known pharmacokinetic/pharmacodynamic relationship at time of invention, and since FDA document merely provides advice on what applicants should do if they plan to pursue bioequivalence, and absent known PK/PD relationship, there is no evidence that skilled artisan would have targeted bioequivalence in first instance.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<span>[4]</span> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1699955998723/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_5" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_5" class="headnoteContent"></div>
<div class="headnote_text">
Prior art patents disclosing formulation technology and dissolution profiles for extended-release drug formulations do not support finding that asserted claims of patents for extended-release formulations of skeletal muscle relaxants containing cyclobenzaprine hydrochloride, which require &ldquo;therapeutically effective&rdquo; plasma concentration, are obvious, since, even if it is assumed that prior patents teach physical drug delivery system and dissolution profile claimed in patents in suit, they reveal nothing about limitation at issue, namely, therapeutically effective pharmacokinetic profile for extended-release cyclobenzaprine formulation.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<span>[5]</span> <span>Patentability/Validity &mdash; Obviousness &mdash; Secondary considerations generally </span> <a href="http://www.bloomberglaw.com/document/1699955998723/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0907" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0907">&#9658;115.0907</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_6" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_6" class="headnoteContent"></div>
<div class="headnoteSlug">JUDICIAL PRACTICE AND PROCEDURE</div>
<div class="headnoteDescriptor">
<span>Procedure &mdash; Burden of proof </span> <a href="http://www.bloomberglaw.com/document/1699955998723/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.35" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.35">&#9658;410.35</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_7" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_7" class="headnoteContent"></div>
<div class="headnote_text">
Fact finder in patent litigation must consider all objective evidence before reaching conclusion on issue of obviousness, and it is therefore improper to make obviousness finding based only on reference to patent and prior art, and to then shift burden to patentee to rebut that finding, since precedent of U.S. Court of Appeals for the Federal Circuit, despite language in some opinions referring to &ldquo;prima facie&rdquo; case of obviousness which must be &ldquo;rebutted&rdquo;
by patentee, requires fact finder to consider all evidence of obviousness and nonobviousness before reaching determination, since U.S. Supreme Court has never imposed or even contemplated formal burden-shifting framework in patent litigation context, and has instead required that all evidence relevant to obviousness or nonobviousness be considered collectively, and since requirement that fact finder consider objective evidence before reaching obviousness determination is sound policy, in that objective considerations, when considered with other obviousness evidence in record, serve as check against hindsight bias.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<span>[6]</span> <span>Patentability/Validity &mdash; Obviousness &mdash; Failure of others to remedy </span> <a href="http://www.bloomberglaw.com/document/1699955998723/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0910" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0910">&#9658;115.0910</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_8" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_8" class="headnoteContent"></div>
<div class="headnote_text">
Evidence that third party pharmaceutical manufacturer tried and failed to develop extended-release formulation of skeletal muscle relaxant containing cyclobenzaprine hydrochloride strongly supports finding that infringement plaintiffs' patents claiming such formulations are not invalid for obviousness, since record shows that third party lost
$10 million in unsuccessful attempt to developing therapeutically effective product, whereas plaintiffs took materially different approach and succeeded, since third party and plaintiffs shared central, common goal of creating therapeutically effective product, despite third party's additional goal of reducing side effects, since third party's failure confirms that therapeutically effective pharmacokinetic profile for extended-release cyclobenzaprine was lacking in prior art and that skilled artisans struggled to attain it, and since such scenario is classic evidence of nonobviousness.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<span>[7]</span> <span>Patentability/Validity &mdash; Obviousness &mdash; Long felt need </span> <a href="http://www.bloomberglaw.com/document/1699955998723/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0909" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0909">&#9658;115.0909</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_9" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_9" class="headnoteContent"></div>
<div class="headnote_text">
Evidence that there was long felt need for therapeutically effective, extended-release formulation of skeletal muscle relaxant containing cyclobenzaprine hydrochloride, and that infringement plaintiffs' drug satisfied that need, supports finding that plaintiffs' patents are not invalid for obviousness, since immediate-release formulation had existed for decades, but its regimen of multiple daily doses led to poor patient compliance, since others tried but failed to develop extended-release version, and since pain-management physician called as witness for plaintiffs testified that patient compliance with medication is important, and that he began prescribing plaintiffs' drug, in part, because of prospect of more convenient dosing for his patients. </div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<span>[8]</span> <span>Patentability/Validity &mdash; Obviousness &mdash; Evidence of </span> <a href="http://www.bloomberglaw.com/document/1699955998723/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0906" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0906">&#9658;115.0906</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_10" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_10" class="headnoteContent"></div>
<div class="headnote_text">
Evidence that pharmacokinetic profile claimed in patent for extended-release version of drug is bioequivalent to PK profile of immediate release version is relevant to determination of whether patent is invalid for obviousness; in present case, however, in which therapeutic effectiveness is claimed limitation of patents for extended-release formulation of skeletal muscle relaxant containing cyclobenzaprine hydrochloride, and it is undisputed that cyclobenzaprine lacked known pharmacokinetic/pharmacodynamic relationship at time of invention, infringement defendants cannot rely on bioequivalence as sole basis for obviousness finding, particularly in view of their heavy burden of proving obviousness by clear and convincing evidence.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<span>[9]</span> <span>Patentability/Validity &mdash; Specification &mdash; Best mode </span> <a href="http://www.bloomberglaw.com/document/1699955998723/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.1107" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.1107">&#9658;115.1107</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_11" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_11" class="headnoteContent"></div>
<div class="headnote_text">
Second prong of best-mode inquiry is objective one that requires fact finder to determine whether specification discloses sufficient information such that person reasonably skilled in art could practice best mode;
second prong is not inquiry concerning whether inventor &ldquo;concealed&rdquo;
best mode, since concealment implicates inventor&rsquo;s state of mind, which is inconsistent with objective inquiry focused on what specification teaches skilled artisan.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<span>[10]</span> <span>Patentability/Validity &mdash; Specification &mdash; Best mode </span> <a href="http://www.bloomberglaw.com/document/1699955998723/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.1107" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.1107">&#9658;115.1107</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_12" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_12" class="headnoteContent"></div>
<div class="headnote_text">
Patents directed to extended-release formulations of skeletal muscle relaxants containing cyclobenzaprine hydrochloride are not invalid for failure to disclose preferred range of dew points for air entering fluid bed machine in which beads are coated with drug and layer of extended-release coating, even though it is undisputed that inventor had subjective belief in such range as best mode, since record shows that dew point is function of other parameters that skilled artisan would manipulate and harmonize in order to create optimal condition for fabricating product in fluid bed, and skilled artisans would consequently expect to attain optimal dew points during ordinary harmonization process by employing routine steps such as controlling humidity and operating fluid bed within normal operating range, and since specification therefore need not expressly disclose optimal dew points in order to enable skilled artisans to practice best mode.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<span>[11]</span> <span>Patentability/Validity &mdash; Specification &mdash; Best mode </span> <a href="http://www.bloomberglaw.com/document/1699955998723/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.1107" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.1107">&#9658;115.1107</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_13" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_13" class="headnoteContent"></div>
<div class="headnote_text">
Principle that allows accused infringer to prove best mode violation where undisclosed subject matter is not strictly within bounds of claims, provided it materially affects claimed invention, is exception to general rule that best mode disclosure requirement only refers to invention defined by claims, and has no application if undisclosed subject matter is within bounds of asserted claims.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">REMEDIES</div>
<div class="headnoteDescriptor">
<span>[12]</span> <span>Non-monetary and injunctive &mdash; Equitable relief &mdash;
Preliminary injunctions &mdash; Patents </span> <a href="http://www.bloomberglaw.com/document/1699955998723/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=505.0707.07" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="505.0707.07">&#9658;505.0707.07</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_14" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_14" class="headnoteContent"></div>
<div class="headnote_text">
Infringement defendants' appeal from order entering injunction against their launch of generic version of drug that is subject of patents in suit is dismissed without prejudice in action in which federal district court held plaintiffs' patents invalid for obviousness, since judgment of invalidity has been reversed and vacated, and defendants thus are no longer prevailing parties or prevailing generic manufacturers, since it is unclear at present stage what ultimate resolution of this matter will be or whether launch of defendants' generic will be deemed authorized, and since it is therefore premature to address defendants' claim for damages against appeal bond, or their arguments regarding circumstances under which, or standards by which, injunction pending appeal may be imposed on prevailing party in action involving abbreviated new drug application.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
  Appeal from the United States District Court for the
District of Delaware, Sue L. Robinson, J.
</p></div>
<span CLASS="page_no" data-cite="676 f 3d 1064" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1064" data-primary-citation="676 F.3d 1063">[*1064]</span> <div id="contentOpinion" printdualcolumn="true"><div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE:  THIS PAGE CONTAINS HEADNOTES. HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="676 f 3d 1065" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1065" data-primary-citation="676 F.3d 1063">[*1065]</span> 
</p></div></div>
<div id="para2" printdualcolumn="true"><p>
  Jonathan E. Singer Fish &amp; Richardson, P.C., of
Wilmington, DE, argued for plaintiff-cross appellant. With him
on the brief were William J. Marsden, Jr. of Minneapolis, MN,
Juanita R. Brooks, of San Diego, CA, and Cherylyn Esoy Mizzo,
of Washington, D.C.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Robert L. Byer, Duane Morris LLP, of Pittsburg, Pennsylvania,
for amici curiae Gregory D o h and Robert C. Kahrl. With him on
the brief were Kristina Caggiano and Elese Hanson.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  James H. Wallace, Jr., Wiley Rein LLP, of Washington, DC,
argued defendants-appellants. With him on the brief were Mark
A. Pacella, Robert J. Scheffel, Matthew J. Dowd, Kevin P.
Anderson and Brian H. Pandya.
<span CLASS="page_no" data-cite="676 f 3d 1066" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1066" data-primary-citation="676 F.3d 1063">[*1066]</span> 
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Before NEWMAN, O'MALLEY, and REYNA, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  O'MALLEY, Circuit Judge.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  After a bench trial, the U.S. District Court for the
District of Delaware found <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3GP0E74GOJ?jcsearch=usp%207387793&amp;summary=yes#jcite">U.S. Patent Nos. 7,387,793</a> <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3H8G833GGJ?jcsearch=usp%207544372&amp;summary=yes#jcite">and
7,544,372</a> invalid as obvious. Case No. 2011-1409 is an appeal
from that judgment. We reverse and vacate the district court's
judgment of invalidity because the district court erred when it
declared the patents in suit invalid as obvious. Specifically,
by failing to consider the lack of a known
pharmacokinetic/pharmacodynamic relationship for the claimed
drug formulation, the trial court erred when it assessed the
importance of the teachings of the prior art to the obviousness
analysis.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As an alternative ground in support of the district court's
judgment invalidating the &prime;<cite>793</cite> and &prime;<cite>372</cite> patents,
the defendants argue that the district court erred when it
found that the patents satisfy the best mode disclosure
requirement. We affirm the district court's best mode ruling.
The evidence supports a finding that the patents in suit enable
one of ordinary skill in the art to practice the inventor's
preferred dew points.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  After invalidating the &prime;<cite>793</cite> and &prime;<cite>372</cite> patents as
obvious, the district court enjoined the defendants &mdash; the
parties who prevailed at trial &mdash; from launching their
generic product pending appeal to this court. That order is
challenged in Case No. <cite>2011-1399</cite>. We dismiss that appeal as
premature because several outstanding issues in the district
court leave uncertain whether the defendants could recover on
their appeal bond.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   I.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Plaintiff Aptalis Pharmatech, Inc. is the owner of the
&prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3GP0E74GOJ?jcsearch=usp%207387793&amp;summary=yes#jcite">793</a> and &prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3H8G833GGJ?jcsearch=usp%207544372&amp;summary=yes#jcite">372</a> patents. Plaintiff Anesta AG, a
wholly owned subsidiary of plaintiff Cephalon, Inc., is the
exclusive licensee of the patents. We refer to the plaintiffs
collectively as Cephalon.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The &prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3GP0E74GOJ?jcsearch=usp%207387793&amp;summary=yes#jcite">793 patent</a> covers a modified-release dosage form of
skeletal muscle relaxants. The &prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3H8G833GGJ?jcsearch=usp%207544372&amp;summary=yes#jcite">372 patent</a> covers a
method of relieving muscle spasms with the formulation
disclosed in the &prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3GP0E74GOJ?jcsearch=usp%207387793&amp;summary=yes#jcite">793 patent</a>. Cephalon markets a drug
covered by the patents under the brand name Amrix. The active
pharmaceutical ingredient <span CLASS="page_no" data-cite="2012 bl 92043 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> in Amrix is cyclobenzaprine
hydrochloride. A single dose of Amrix releases cyclobenzaprine
hydrochloride in the body during a twenty-four-hour period.
Immediate-release formulations, by contrast, release the drug
in a shorter amount of time and require multiple daily doses.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The &prime;<cite>793</cite> and &prime;<cite>372</cite> patents share the same
specification and, as relevant to this appeal, have the same
limitations in claims 1-3. Claim 1 recites a dosage form of a
skeletal muscle relaxant (in the &prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3GP0E74GOJ?jcsearch=usp%207387793&amp;summary=yes#jcite">793 patent</a>) and a
method of relieving muscle spasms (in the &prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3H8G833GGJ?jcsearch=usp%207544372&amp;summary=yes#jcite">372 patent</a>),
which, in relevant part, "provides [a] therapeutically
effective plasma concentration over a period of 24 hours to
treat muscle spasm associated with painful musculoskeletal
conditions. . . ." &prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3GP0E74GOJ?jcsearch=usp%207387793&amp;summary=yes#jcite">793 patent</a> col.10 ll.23, 43-46 (filed
Nov. 14, 2003); &prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3H8G833GGJ?jcsearch=usp%207544372&amp;summary=yes#jcite">372 patent</a> col.10 ll.21, 43-46 (filed
Feb. 6, 2008). Claim 2 depends on claim 1 and specifies the
claimed skeletal muscle relaxant as cyclobenzaprine
hydrochloride. &prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3GP0E74GOJ?jcsearch=usp%207387793&amp;summary=yes#jcite">793 patent</a> col.10 ll.62-64; &prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3H8G833GGJ?jcsearch=usp%207544372&amp;summary=yes#jcite">372
patent</a> col.10 ll.61-62. Claim 3 depends on claim 2 and
specifies the following pharmacokinetic values:
<span CLASS="page_no" data-cite="102 uspq 2d 1764" data-cite-type="ReporterOfDecisions" data-cite-pageno="1764" data-primary-citation="102 U.S.P.Q.2d 1760">[**1764]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  [A] maximum blood plasma concentration
  (Cmax) within the range of about 80% to
  125% of about 20 ng/mL of cyclobenzaprine HC1 and an
  AUC0-168 within the range of about 80% to
  125% of about 740 ng hr/mL and a Tmax
  within the range of 80% to 125% of about 7 hours
  following oral administration. . . .
<span CLASS="page_no" data-cite="676 f 3d 1067" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1067" data-primary-citation="676 F.3d 1063">[*1067]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
&prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3GP0E74GOJ?jcsearch=usp%207387793&amp;summary=yes#jcite">793 patent</a> col.10 l.65-col.11 l.5; &prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3H8G833GGJ?jcsearch=usp%207544372&amp;summary=yes#jcite">372 patent</a>
eol.10 l.63-col.11 l.3.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Pharmacokinetics is the study of what a person's body does to a
drug after administration. The pharmacokinetic ("PK") values
recited in claim 3 measure various characteristics about the
drug's behavior in a patient's blood plasma. Cmax as
claim 3 alludes, represents the maximum concentration of the
drug in a person's blood plasma. AUC0-168 represents
the area under the blood plasma concentration curve, or, in
other words, the body's total exposure to the drug.
Tmax represents the time after administration when
the maximum concentration of the drug in the blood plasma
(Cmax occurs.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To formulate a therapeutically effective, extended-release
version of cyclobenzaprine hydrochloride, the inventors had to
ascertain the correct pharmacokinetic/pharmacodynamic ("PK/PD")
profile. The PK side of the relationship &mdash; what a
person's body does to the drug &mdash; includes the
Cmax AUC, and Tmax as identified in claim
3. The PD side of the relationship describes the effect that a
drug renders on a person's body. The PD of cyclobenzaprine
hydrochloride is the relief of muscle spasms.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The determination of a PK profile is a quantitative exercise.
The determination of PD, or therapeutic effectiveness, however,
is a qualitative exercise. As one of Cephalon's experts, Dr.
Stanley Davis, explained, a therapeutically effective plasma
concentration is "a concentration that the formulation provides
when the formulation works." The district court, likewise,
construed the claim limitation "therapeutically effective
plasma concentration" to mean "the amount of a drug required to
produce the therapeutic result."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  One of the patents' inventors, Dr. Gopi Venkatesh, testified at
trial about how he and his co-inventor, Dr. James Clevenger,
ascertained the correct PK/PD profile for <span CLASS="page_no" data-cite="2012 bl 92043 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> the patented
formulation. First, they estimated PK values with computer
models. They started by creating PK profiles for the
immediate-release formulation. The immediate-release
formulation is dosed at 10 mg. Using immediate-release PK data,
the inventors created models for twice-a-day dosing and
three-times-a-day dosing at 10 mg per dose. Then, they drew on
that data to create a model for a single, 30 mg dose. The
inventors then created an in vitro dissolution profile, which
modeled how much drug would be released over time if the
formulation with the model PK values were placed in a solution
such as water. Finally, the inventors tested a formulation with
the model PK values and dissolution profile in a clinic.
Clinical test results confirmed that the formulation was
therapeutically effective.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   II.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The defendants, Mylan Pharmaceuticals Inc. and Mylan Inc.
(collectively, "Mylan"), and Par Pharmaceutical, Inc. ("Par"),
filed abbreviated new drug applications ("ANDAs") for generic
versions of extended-release cyclobenzaprine hydrochloride. In
support of their ANDAs, Mylan and Par filed "Paragraph IV"
certifications, in which they alleged that their generic
products would not infringe the &prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3GP0E74GOJ?jcsearch=usp%207387793&amp;summary=yes#jcite">793 patent</a>, or that the
patent was invalid or unenforceable. <i>See</i>
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)(vii)(IV)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(jX2)(A)(vii)(rV) (2006). The U.S. Food and Drug
Administration ("FDA") approved both defendants' applications.
Because Mylan was the first party to file a Paragraph IV
certification, the FDA granted Mylan a 180-day exclusive
marketing period for its generic product.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Cephalon sued Mylan and Par for patent infringement, claiming
that the defendants' filing of their ANDAs infringed the
&prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3GP0E74GOJ?jcsearch=usp%207387793&amp;summary=yes#jcite">793 patent</a>. <i>See</i> <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2) (2006
<span CLASS="page_no" data-cite="676 f 3d 1068" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1068" data-primary-citation="676 F.3d 1063">[*1068]</span> 
&amp; Supp. IV 2010). The FDA stayed Mylan's exclusive marketing
period for thirty months because of the litigation. The
district court conducted a bench trial in September and October
2010. Rather than ruling from the bench, the district court
took the matter under advisement to pre-pare a written opinion.
The end of the FDA's thirty-month stay approached as the
parties waited for the district court's opinion. On April 8,
2011, the district court, sua sponte, temporarily enjoined
Mylan from launching its generic product pending the issuance
of an opinion. The thirty-month stay expired on April 17, 2011.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court issued its written opinion on May 12, 2011.
It ruled that Mylan's and Par's products infringed the
&prime;793 and &prime;372 patents, <span CLASS="page_no" data-cite="102 uspq 2d 1765" data-cite-type="ReporterOfDecisions" data-cite-pageno="1765" data-primary-citation="102 U.S.P.Q.2d 1760">[**1765]</span> but that Cephalon's asserted
patent claims were invalid as obvious. The district court
entered judgment of invalidity in favor of Mylan and Par. The
district court's sua sponte injunction expired by its own terms
upon entry of judgment.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On May 13, 2011, the day after the district court entered
judgment, Mylan launched its generic product. On May 15, 2011,
Cephalon moved for an injunction to bar Mylan's launch pending
appeal and to recapture product already released. Cephalon
argued that it was likely to prevail on appeal because it
believed the district court had made a number of errors in its
obviousness analysis. In response, the district court conceded
certain errors and modified some <span CLASS="page_no" data-cite="2012 bl 92043 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> of its findings, but
reaffirmed its obviousness ruling. Notwithstanding that it
affirmed Mylan's victory, the district court granted Cephalon's
motion for injunctive relief and issued an injunction pending
appeal to this court. The district court expressed uncertainty
about whether this court would affirm its invalidity ruling and
found that Cephalon was "just as likely as not" to succeed on
appeal. The district court then found that the potential harm
to Cephalon and a lack of a corresponding threat of harm to
Mylan weighed in favor of an injunction.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mylan appealed the injunction. Cephalon appealed the district
court's invalidity ruling. Mylan moved this court to stay the
injunction pending resolution of the appeal, and this court did
so temporarily, pending full briefing of Mylan's motion. <i>In</i>
<i>re Cyclobenzaprine Hydrochloride Extended-Release Capsule</i>
<i>Patent Litig.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FGKUO003?jcsearch=424%20f%20appx%20952&amp;summary=yes#jcite">424 Fed.Appx. 952</a> (Fed. Cir. 2011) (order
granting immediate stay of preliminary injunction). After
briefing from the parties, this court lifted the temporary
stay, but declined to require that Mylan recall any product it
had sold while the stay was in place. <i>In re Cyclobenzaprine</i>
<i>Hydrochloride Extended-Release Capsule Patent Litig.</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FLU5I003?jcsearch=449%20f%20appx%2035&amp;summary=yes#jcite">449 Fed.Appx. 35</a> (Fed. Cir. 2011) (order granting temporary stay in
part). We now consider both appeals on their merits.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                  III.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We address the district court's obviousness ruling first. A
patent may not issue "if the differences between the subject
matter sought to be patented and the prior art are such that
the subject matter as a whole would have been obvious at the
time the invention was made to a person having ordinary skill
in the art to which said subject matter pertains."
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103(a)&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>(a) (2006). Obviousness is a question of law based on
underlying factual findings: (1) the scope and content of the
prior art; (2) the differences between the claims and the prior
art; (3) the level of ordinary skill in the art; and (4)
objective considerations of nonobviousness. <i>Graham v. John</i>
<i>Deere Co.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">383 U.S. 1</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">17-18</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=86%20supreme%20court%20684&amp;summary=yes#jcite">86 S.Ct. 684</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=15%20l%20ed%202d%20545&amp;summary=yes#jcite">15 L.Ed.2d 545</a>
(1966). Generally, a party seeking to invalidate a patent as
obvious must "demonstrate `by clear and
<span CLASS="page_no" data-cite="676 f 3d 1069" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1069" data-primary-citation="676 F.3d 1063">[*1069]</span> 
convincing evidence that a skilled artisan would have had
reason to combine the teaching of the prior art references to
achieve the claimed invention, and that the skilled artisan
would have had a reasonable expectation of success from doing
so.'" <i>Procter &amp; Gamble Co. v. Teva Pharms. USA</i>
<i>Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1B3GOU003?jcsearch=566%20f%203d%20989&amp;summary=yes#jcite">566 F.3d 989</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1B3GOU003?jcsearch=566%20f%203d%20989&amp;summary=yes#jcite">994</a> (Fed. Cir. 2009) (quoting
<i>Pfizer, Inc. v. Apotex, Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X16HK1U003?jcsearch=480%20f%203d%201348&amp;summary=yes#jcite">480 F.3d 1348</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X16HK1U003?jcsearch=480%20f%203d%201348&amp;summary=yes#jcite">1361</a>
(Fed. Cir. 2007)). <i>See also Amgen, Inc. v. F. Hoffman-La</i>
<i>Roche Ltd.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1BN634003?jcsearch=580%20f%203d%201340&amp;summary=yes#jcite">580 F.3d 1340</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1BN634003?jcsearch=580%20f%203d%201340&amp;summary=yes#jcite">1362</a> (Fed. Cir. 2009) ("An
obviousness determination requires that a skilled artisan would
have perceived a reasonable expectation of success in making
the invention in light of the prior art.") (citations omitted).
The Supreme Court has warned, however, that, while an analysis
of any teaching, suggestion, or motivation to combine known
elements is useful to an obviousness analysis, the overall
obviousness inquiry must be expansive and flexible. <i>KSR</i>
<i>Int'l Co. v. Teleflex, Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. 398</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">415</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">419</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRIK7VQNB5G0?jcsearch=167%20l%20ed%202d%20705&amp;summary=yes#jcite">167 L.Ed.2d 705</a> (2007).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In reviewing a district court's obviousness ruling after a
bench trial, we review its legal conclusion de novo, but we
review its underlying factual findings for <span CLASS="page_no" data-cite="2012 bl 92043 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> clear error.
<i>Procter &amp; Gamble</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1B3GOU003?jcsearch=566%20f%203d%20989&amp;summary=yes#jcite">566 F.3d at 993-94</a>. The
clear-error standard of review applied to a district court's
factual findings demands that we defer to those findings unless
we are left with "a definite and firm conviction that a mistake
has been committed." <i>United States v. U.S. Gypsum Co.</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C1AJ?jcsearch=333%20us%20364&amp;summary=yes#jcite">333 U.S. 364</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C1AJ?jcsearch=333%20us%20364&amp;summary=yes#jcite">395</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C1AJ?jcsearch=68%20supreme%20court%20525&amp;summary=yes#jcite">68 S.Ct. 525</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C1AJ?jcsearch=92%20l%20ed%20746&amp;summary=yes#jcite">92 L.Ed. 746</a> (1948). While we
afford deference to a district court's factual findings,
however, we retain plenary review to determine whether, as a
legal matter, the evidence satisfies the clear-and-convincing
standard of proof. <i>Procter &amp; Gamble</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1B3GOU003?jcsearch=566%20f%203d%20989&amp;summary=yes#jcite">566 F.3d at 993-94</a>. Indeed, the Supreme Court recently confirmed that a
party asserting an obviousness claim bears that high burden of
persuasion. <i>Microsoft Corp. v. 141 Ltd.<span CLASS="page_no" data-cite="102 uspq 2d 1766" data-cite-type="ReporterOfDecisions" data-cite-pageno="1766" data-primary-citation="102 U.S.P.Q.2d 1760">[**1766]</span> </i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FI916003?jcsearch=98%20U.S.P.Q.2d%201857&amp;summary=yes#jcite">___ U.S. ___</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">131 S.Ct. 2238</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">2242</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FI916003?jcsearch=180%20l%20ed%202d%20131&amp;summary=yes#jcite">180 L.Ed.2d 131</a> (2011).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   A.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We find that the district court's legal conclusion that
bioequivalence alone was sufficient to render the claims at
issue obvious was in error. We also find clear error in a
number of the district court's factual findings, as identified
below.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The obviousness inquiry in this case is focused on
bioequivalence. The concept of bioequivalence means the body is
exposed to the same amount of active pharmaceutical ingredient
at the same rate after administration of either an
immediate-release or extended-release formulation. The district
court found the asserted claims obvious because it believed the
claimed extended-release PK profile is bioequivalent to the
immediate-release PK profile. Mylan agrees with the district
court's approach of resting its obviousness finding on
bioequivalence. Cephalon, however, argues that the district
court placed undue weight on bioequivalence and, as a result,
misinterpreted the proffered prior art references.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span id="headnote_ref_pq2-dec_914849">[1]</span> We agree with Cephalon. The district court treated
bioequivalence as the end of its inquiry when the court found
that it would have been obvious to a person having ordinary
skill in the art to target extended-release PK values
"mirroring" &mdash; in other words, bioequivalent to &mdash;
those of the immediate-release cyclobenzaprine formulation. The
district court, however, was also required to consider the
asserted claims' limitation requiring therapeutic
effectiveness, and whether it would have been obvious to one of
ordinary skill in the art at the time of the invention that a
bioequivalent PK value would satisfy that limitation.
<i>Graham</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">383 U.S. at 17-18</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=86%20supreme%20court%20684&amp;summary=yes#jcite">86 S.Ct. 684</a> (making clear
that "differences between the prior art and <i>the claims</i>
<i>at</i>
<span CLASS="page_no" data-cite="676 f 3d 1070" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1070" data-primary-citation="676 F.3d 1063">[*1070]</span> 
<i>issue</i> are to be ascertained") (emphasis added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mylan and Par argued, and the district court agreed, that the
undisputed fact that cyclobenzaprine lacked a known PK/PD
relationship at the time of invention was irrelevant. Without
such a known relationship, however, skilled artisans could not
predict whether any particular PK profile, including a
bioequivalent one, would produce a therapeutically effective
formulation. Dr. Davis, Cephalon's expert, testified that
cyclobenzaprine's "mode of action was not really well known and
there [was] certainly no clear relationship between a given
pharmacokinetic profile and the pharmacodynamic effect, what it
actually does to the body." One of the defendants' experts, Dr.
Gordon <span CLASS="page_no" data-cite="2012 bl 92043 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> Amidon, acknowledged that there was nothing in the prior
art or published literature "that would help a person skilled
in the art determine a therapeutically effective plasma
concentration over a 24-hour period."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mylan and Par did not dispute that cyclobenzaprine lacked a
known PK/PD relationship. Rather, they attempted to avoid that
fact in two ways. First, they asserted the truism that skilled
artisans would need only a reasonable expectation of success
and would not need to be certain of what a particular PK
profile would yield. See Defs.' Resp. &amp; Reply Br. 26.
Second, Mylan and Par argued to the district court that the
patents in suit lack sufficient written description to support
the "therapeutically effective" limitation. Lack of written
description, however, is a separate defense, which the
defendants do not advance on appeal. For purposes of
obviousness, therefore, we must accept as true that
cyclobenzaprine lacked a known PK/PD relationship at the time
of invention, and that the asserted claims contain a valid
"therapeutically effective" limitation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court misapprehended the importance of the lack of
a known PK/PD relationship. The district court stated that
"[t]he lack of a PK/PD relationship is of no moment . . . given
that one of ordinary skill in the art would expect the extended
release formulation to have the same PD effect on the body if
it has the immediate release formulation's PK profile." That
statement contains an inherent contradiction. By stating that
skilled artisans would assume that the immediate-release and
extended-release PK profiles produce the same PD effect, the
district court was assuming that a known PK/PD relationship
existed for the immediate-release formulation. Because all
experts and parties agree, however, that skilled artisans did
<i>not</i> know the PK/PD relationship even for the
immediate-release formulation, there was no way to match the
dosage for the extended-release formulation to achieve a known
therapeutic effect. The district court, therefore, could not
find obviousness without finding that the prior art would have
taught or suggested a therapeutically effective formulation to
one of ordinary skill in <span CLASS="page_no" data-cite="102 uspq 2d 1767" data-cite-type="ReporterOfDecisions" data-cite-pageno="1767" data-primary-citation="102 U.S.P.Q.2d 1760">[**1767]</span> the art. The record lacks any such
evidence. While it may have been obvious to experiment with the
use of the same PK profile when contemplating an
extended-release formulation, there is nothing to indicate that
a skilled artisan would have had a reasonable expectation that
such an experiment would succeed in being therapeutically
effective. <i>See Procter &amp; Gamble</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1B3GOU003?jcsearch=566%20f%203d%20989&amp;summary=yes#jcite">566 F.3d at 994</a>
(requiring a reasonable expectation of success to prove
obviousness).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This distinction is important. Where a skilled artisan merely
pursues "known options" from "a finite number of identified,
predictable solutions," the resulting invention is obvious
under <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103&amp;summary=yes#jcite">Section 103</a>. <i>KSR</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. at 421</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>. Where, however, a defendant urges an obviousness
<span CLASS="page_no" data-cite="676 f 3d 1071" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1071" data-primary-citation="676 F.3d 1063">[*1071]</span> 
finding by "merely throwing] metaphorical darts at a board"
in hopes of arriving at a successful result, but "the prior
art gave either no indication of which parameters were critical <span CLASS="page_no" data-cite="2012 bl 92043 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> or
no direction as to which of many possible choices is likely to
be successful," courts should reject "hindsight claims of
obviousness." <i>In re Kubin</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1ASIN4003?jcsearch=561%20f%203d%201351&amp;summary=yes#jcite">561 F.3d 1351</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1ASIN4003?jcsearch=561%20f%203d%201351&amp;summary=yes#jcite">1359</a>
(Fed. Cir. 2009) (quoting <i>In re O'Farrell</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XAFKES?jcsearch=853%20f%202d%20894&amp;summary=yes#jcite">853 F.2d 894</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XAFKES?jcsearch=853%20f%202d%20894&amp;summary=yes#jcite">903</a> (Fed. Cir. 1988)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   B.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court's failure to appreciate the lack of a known
PK/PD relationship for <i>any</i> formulation of
cyclobenzaprine rendered deficient its analysis of the evidence
that Mylan and Par offered to prove the claimed PK values
obvious and its analysis of the implications of that evidence
on its legal conclusion of obviousness. We explain below why
the district court's analysis was deficient.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   1.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court found that a skilled artisan could calculate
the claimed AUC and Tmax by conducting what it
called "routine experimentation": creating computer models
based on data from articles by Winchell and Hucker, and PK data
for Flexeril, the branded immediate-release formulation. The
district court relied on the testimony of Dr. Amidon in
interpreting those prior art references.<a HREF="#fn100" name="fnref_fn100">[fn1]</a> Mylan and Par
agree with the district court, arguing that the evidence shows
that "one of ordinary skill in the art could readily convert
the known pharmacokinetic data for Flexeril&reg; administered
10 mg three times a day to an equivalent pharmacokinetic
profile for a single daily 30 mg administration." Defs.' Resp.
&amp; Reply Br. 40.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Amidon's testimony, however, was insufficient to support
the conclusion that a skilled artisan would reasonably expect
to achieve a therapeutically effective AUC and Tmax
Indeed, it was actually inconsistent with that conclusion. As
Dr. Amidon explained, Winchell reveals that cyclobenzaprine is
linear, which means that blood plasma concentration increases
proportionally to dosage. The fact that a skilled artisan could
have predicted a particular blood plasma concentration,
however, does not mean that such knowledge would have provided
a skilled artisan a reasonable expectation of success in
calculating a blood plasma concentration that was
therapeutically effective. As Dr. Amidon also explained,
Winchell suggests that cyclobenzaprine is well absorbed in the
body. That information, however, pertains to the body's
physical absorption of the drug rather than the correct PK/PD
relationship. As Dr. Amidon further explained, Winchell
provides PK values for immediate-release cyclobenzaprine, and
Hucker provides plasma concentration time curves for the
immediate-release formulation. Without a known PK/PD
relationship, however, immediate-release PK values are of
little use in calculating extended-release values, because
there is no proof that a skilled artisan would expect the
extended-release values to produce a therapeutic effect solely
because they are drawn from immediate-release values.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The evidence on which the district court relied to find the
claimed Cmax obvious
<span CLASS="page_no" data-cite="676 f 3d 1072" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1072" data-primary-citation="676 F.3d 1063">[*1072]</span> 
similarly focuses on bare PK values rather than the PD
effect that the PK values could be expected to produce. The
district court found that Winchell "undisputably [sic]"
disclosed the claimed Cmax Winchell indicates <span CLASS="page_no" data-cite="2012 bl 92043 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> that,
after subjects are dosed every eight hours for seven days at 10
mg/dose, subjects have a <span CLASS="page_no" data-cite="102 uspq 2d 1768" data-cite-type="ReporterOfDecisions" data-cite-pageno="1768" data-primary-citation="102 U.S.P.Q.2d 1760">[**1768]</span> Cmax of 25.9 ng/ml. That
value is 129.5% of 20 ng/ml. Claim 3 of the patents in suit
claims a Cmax range of about 80% to 125% of about 20
ng/ml. The district court, however, cited no evidence
specifically indicating that a cyclobenzaprine PK profile with
a Cmax of 129.5% of 20 ng/ml would be expected to
yield the same therapeutic effect as that with a
Cmax range of about 80% to 125% of about 20 ng/ml.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court, moreover, cited nothing to support a
finding that the claimed Cmax range of about 80% to
125% of about 20 ng/ml even encompasses Winchell's
Cmax of 129.5% of 20 ng/ml. Claim 3 does specify
that the claimed range is <i>about</i> 80% to 125% of
<i>about</i> 20 ng/ml. The district court construed the term
"about" to mean "approximately," but failed to cite any
evidence indicating that 129.5% of 20 ng/ml is approximately
125% of 20 ng/ml. The parties have not directed us to any such
proof.<a HREF="#fn200" name="fnref_fn200">[fn2]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court found persuasive Dr. Amidon's ultimate
opinion that a skilled artisan could expect to achieve efficacy
by relying on the Winchell and Hucker articles to estimate a PK
profile for an extended-release formulation by using computer
software. While we would normally afford the district court
deference in crediting such an opinion, we cannot do so here
because Dr. Amidon failed to discuss why, in the specific
context of cyclobenzaprine, a skilled artisan would expect PK
values drawn from the prior art to yield a therapeutically
effective formulation. Indeed, the portion of Dr. Amidon's
testimony on which the district court relied conflicts with his
acknowledgement that the prior art and published literature
lacked any guidance to help a skilled artisan determine a
therapeutically effective, extended-release plasma
concentration. Dr. Amidon's own computer modeling, moreover,
failed to generate PK values within the claimed ranges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span id="headnote_ref_pq2-dec_914850">[2]</span> Mylan and Par rely extensively on Dr. Amidon's testimony about
the prior art in arguing that it would have been obvious to try
to develop extended-release cyclobenzaprine bioequivalent to
the immediate-release PK profile, and that skilled artisans
would have had a reasonable expectation of success in doing so.
The insufficiency of that evidence demonstrates why the
defendants' argument stands on a weak foundation. Evidence of
obviousness, especially when that evidence is proffered in
support of an "obvious-to-try" theory, is insufficient unless
it indicates that the possible options skilled artisans would
have encountered were "finite," "small," or "easily traversed,"
and that skilled artisans would have had a reason to select the
route that produced the claimed invention. <i>Ortho-McNeil</i>
<i>Pharm., Inc. v. Mylan Labs., Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X18N34Q003?jcsearch=520%20f%203d%201358&amp;summary=yes#jcite">520 F.3d 1358</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X18N34Q003?jcsearch=520%20f%203d%201358&amp;summary=yes#jcite">1364</a>
(Fed. Cir. 2008) (citing <i>KSR</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. at 421</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>). While it is true that
<span CLASS="page_no" data-cite="676 f 3d 1073" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1073" data-primary-citation="676 F.3d 1063">[*1073]</span> 
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103&amp;summary=yes#jcite">Section 103</a> bars patentability unless "the improvement is more than
the predictable use of prior art elements according to their
established functions," <i>KSR</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. at 417</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>, where the prior art, at best, "[gives] only general
guidance as to the particular form of the claimed invention or
how to achieve it," relying <span CLASS="page_no" data-cite="2012 bl 92043 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> on an "obvious-to-try" theory to
support an obviousness finding is "impermissible." <i>In re</i>
<i>Kubin</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1ASIN4003?jcsearch=561%20f%203d%201351&amp;summary=yes#jcite">561 F.3d at 1359</a> (quoting <i>In re O'Farrell</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XAFKES?jcsearch=853%20f%202d%20894&amp;summary=yes#jcite">853 F.2d at 903</a>). Nothing in Dr. Amidon's testimony sheds light
on why a skilled artisan would have chosen a bioequivalent PK
profile in the absence of a known PK/PD relationship for
cyclobenzaprine. Thus, the absence of such testimony suggests
that skilled artisans would not have encountered finite, small,
or easily traversed options in developing a therapeutically
effective, extended-release formulation. <i>See <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1ASIN4003?jcsearch=561%20F.3d%20at%201359&amp;summary=yes#jcite">id</a>.</i> And,
there is nothing in the record to support the conclusion that
what the co-inventors did here was no more than a "predictable
use of known prior art elements." <i>KSR</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. at 417</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Winchell and Hucker articles, the Flexeril data, and the
defense experts' interpretation of those references, fail to
indicate that a skilled artisan would have reasonably expected
to calculate therapeutically effective PK values based on those
references. While the district court's assessment of this
evidence <span CLASS="page_no" data-cite="102 uspq 2d 1769" data-cite-type="ReporterOfDecisions" data-cite-pageno="1769" data-primary-citation="102 U.S.P.Q.2d 1760">[**1769]</span> may be understandable given its predicate mistake
regarding the absence of a known PK/PD profile for the
immediate-release formulation, it was, nonetheless, clear
error.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   2.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court also relied on other evidence to support its
obviousness analysis. The district court's factual conclusions
from this evidence again were clearly erroneous, however, and
the weight given to them in the court's obviousness conclusion
was undue.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span id="headnote_ref_pq2-dec_914851">[3]</span> The district court noted that Dr. Clevenger, co-inventor of the
patents in suit, created computer models of the claimed PK
values after he reviewed the Flexeril PK data. The district
court cited Dr. Clevenger's approach when it concluded that the
claimed AUC and Tmax could be obtained by "routine
experimentation." In relying on Dr. Clevenger's testimony, the
district court merely retraced the inventor's steps. This
hindsight analysis is inappropriate because obviousness must be
assessed at the time the invention was made. <i>See</i>
<i>Ortho-McNeil</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X18N34Q003?jcsearch=520%20f%203d%201358&amp;summary=yes#jcite">520 F.3d at 1364</a> (noting that
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103(a)&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>(a) directs an inquiry into whether the subject matter
as a whole "would have been obvious at the time the invention
was made"). Like the district court, Mylan and Par rely on Dr.
Clevenger's testimony for the proposition that "one of ordinary
skill could use the available software . . . and estimate the
parameters identified by Mylan's experts." Defs.' Resp.
&amp; Reply Br. 41. Like the district court, however, Mylan and Par
employ hindsight analysis.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Clevenger's testimony, moreover, does not support the
proposition for which the district court cited it. The district
court found significant Dr. Clevenger's testimony that "[i]t
can be assumed that the [immediate-release product] produced a
therapeutic effect . . ." and that "if we get something similar
to those blood levels . . . then we, too, will have a product
that will produce a therapeutic effect." The district court,
however, omitted the next exchange in Dr. Clevenger's
examination: "[Question:] . . . So the idea is that if the
blood levels were similar to Flexeril, then hopefully, the
effect would be similar &mdash; the therapeutic effect would be
<span CLASS="page_no" data-cite="2012 bl 92043 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> similar to Flexeril? [Answer:] Hopefully. Depends on the
relationship between blood levels and
<span CLASS="page_no" data-cite="676 f 3d 1074" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1074" data-primary-citation="676 F.3d 1063">[*1074]</span> 
therapeutic effect." The district court later attempted to
minimize the importance of Dr. Clevenger's omitted testimony,
concluding that "this testimony simply shows that the inventor
needed to verify his results in the lab. Obviousness calls for
an expectation of success, not a guarantee." A plain reading of
the testimony, however, indicates that Dr. Clevenger never
expressed even an expectation of success. He merely testified
that, whether blood levels similar to those produced by
Flexeril would produce a therapeutic effect similar to that of
Flexeril, depended on the relationship between blood levels and
therapeutic effectiveness &mdash; a relationship that all
concede was unknown.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court also relied on an FDA guidance document,
which it found directed skilled artisans to pursue
bioequivalence when formulating extended-release formulations.
The title of the document the district court cited is "Guidance
for Industry." The district court found that the document sets
forth an FDA directive that an extended-release dosage form
have the same AUC and Cmax of an already-approved
immediate-release formulation. The FDA document, however,
states that its purpose is "to provide recommendations to
sponsors and/or applicants planning to include . . .
bioequivalence information" in applications. The document
provides advice on what they should do <i>if</i> they plan to
pursue bioequivalence. The document provides little support for
an obviousness finding here, because, in the absence of a known
PK/PD relationship for cyclobenzaprine, there is no evidence
that a skilled artisan would have targeted bioequivalence in
the first instance.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  One judge of our court has observed that the FDA's publishing
of approval requirements for extended-release formulations does
not necessarily render obvious a drug that meets those
requirements, because "knowledge of the goal does not render
its achievement obvious." <i>Abbott Labs., Inc. v. Sandoz,</i>
<i>Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X19R7I0003?jcsearch=544%20f%203d%201341&amp;summary=yes#jcite">544 F.3d 1341</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X19R7I0003?jcsearch=544%20f%203d%201341&amp;summary=yes#jcite">1352</a> (Fed. Cir. 2009). That observation
is particularly salient here because Mylan and Par fail to
demonstrate that skilled artisans would have even viewed
bioequivalence as the goal when creating an extended-release
cyclobenzaprine formulation. Indeed, while there might have
been a desire for an extended-release formulation, there is no
evidence that skilled artisans would have known how to achieve
it. <i>See Cardiac Pacemakers, Inc. v. St. Jude Med.,</i>
<i>Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XFPGH2?jcsearch=381%20f%203d%201371&amp;summary=yes#jcite">381 F.3d 1371</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XFPGH2?jcsearch=381%20f%203d%201371&amp;summary=yes#jcite">1377</a> (Fed. Cir. 2004) ("Recognition <span CLASS="page_no" data-cite="102 uspq 2d 1770" data-cite-type="ReporterOfDecisions" data-cite-pageno="1770" data-primary-citation="102 U.S.P.Q.2d 1760">[**1770]</span> of
a need does not render obvious the achievement that meets that
need. . . . Recognition of an unsolved problem does not render
the solution obvious.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   3.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, the district court relied on two other prior
art references, neither of which supports a finding that the
"therapeutically effective" limitation is obvious. Those
references &mdash; <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X30OG820H8J?jcsearch=usp%206344215&amp;summary=yes#jcite">U.S. Patent No. 6,344,215</a> and European
Patent Application No. 518,-263A1 ("Urban") &mdash; disclose
formulation technology and dissolution profiles rather than
pharmacokinetics. The Urban reference discloses a micropellet
<span CLASS="page_no" data-cite="2012 bl 92043 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[***11]</span> that can be used for an extended-release formulation. It lists
cyclobenzaprine as a suitable medicament for the formulation.
The &prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X30OG820H8J?jcsearch=usp%206344215&amp;summary=yes#jcite">215 patent</a> &mdash; Dr. Venkatesh is the named
inventor &mdash; discloses a multiparticulate dosage form, for
use with methylphenidate, that features the same dissolution
profile claimed in the patents in suit. The district court
believed that it would have been obvious to use the same drug
delivery system because it had already been proven effective
with methylphenidate. Mylan and Par, likewise, argue that
"[t]he only meaningful structural difference between the
asserted claims of the &prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3GP0E74GOJ?jcsearch=usp%207387793&amp;summary=yes#jcite">793 patent</a> and
<span CLASS="page_no" data-cite="676 f 3d 1075" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1075" data-primary-citation="676 F.3d 1063">[*1075]</span> 
&prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X30OG820H8J?jcsearch=usp%206344215&amp;summary=yes#jcite">215 patent</a> was the active ingredient,
cyclobenzaprine versus methylphenidate." Defs.' Resp.
&amp; Reply Br. 8.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span id="headnote_ref_pq2-dec_914852">[4]</span> Even if the &prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X30OG820H8J?jcsearch=usp%206344215&amp;summary=yes#jcite">215 patent</a> and Urban teach the claimed
physical drug delivery system and dissolution profile, they
reveal nothing about the critical limitation at issue here: a
therapeutically effective PK profile. Cephalon has acknowledged
that the structure of the drug delivery system and the
dissolution profile are not novel aspects of the claimed
invention. Oral Argument at 22:40, <i>available at</i>
http://www.cafc.uscourts.gov/oral-argument-recordings/
2011-1399/all. Urban and the &prime;<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X30OG820H8J?jcsearch=usp%206344215&amp;summary=yes#jcite">215 patent</a> provide no
support for the district court's obviousness finding with
respect to pharmacokinetics.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   C.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  After the district court found that Mylan and Par proved the
asserted claims obvious, it considered Cephalon's proof of
objective considerations of nonobviousness to determine whether
Cephalon's proofs were sufficient to "rebut" that obviousness
determination. Specifically, the district court considered
Cephalon's evidence of the failure of others to make the
patented invention; longfelt but unsolved needs fulfilled by
the patented invention; commercial success of the patented
invention; and unexpected results produced by the patented
invention. <i>See Graham</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">383 U.S. at 17-18</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=86%20supreme%20court%20684&amp;summary=yes#jcite">86 S.Ct. 684</a>; <i>Pfizer, Inc. v. Apotex, Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X16HK1U003?jcsearch=480%20f%203d%201348&amp;summary=yes#jcite">480 F.3d 1348</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X16HK1U003?jcsearch=480%20f%203d%201348&amp;summary=yes#jcite">1369</a>
(Fed. Cir. 2007). The district court found Cephalon's evidence
insufficient to rebut Mylan's and Par's showing. The district
court erred, however, by making its finding that the patents in
suit were obvious before it considered the objective
considerations and by shifting the burden of persuasion to
Cephalon. In doing so, the district court contravened this
court's precedent requiring that a fact finder consider all
evidence relating to obviousness before finding a patent
invalid on those grounds, and the court imposed a
burden-shifting framework in a context in which none exists.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   1.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The premature nature of the court's obviousness finding is
apparent. Before it reached the objective considerations, the
district court stated that the claimed PK profile "would have
been obvious to one of skill in the art at the time of the
invention" and that "a person of ordinary skill in the
art would have been motivated to take a group of known elements to
create an extended release version of cyclobenzaprine, and
[would have had] a reasonable expectation of success in doing
so." It was not until after the district court found the
asserted claims obvious that it proceeded to analyze the
objective <span CLASS="page_no" data-cite="2012 bl 92043 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[***12]</span> considerations, or what it called the "secondary
considerations."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   2.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court's error is understandable because this court
has inconsistently articulated the burden of proof applicable
to an obviousness defense in district court litigation. It was
error nonetheless.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span id="headnote_ref_pq2-dec_914853">[5]</span> In <i>Stratoflex, Inc. v. Aeroquip Corp.</i>, we held that a
fact finder in district court litigation may not defer
examination of the objective considerations until after the
fact finder makes an obviousness finding:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It is jurisprudentially inappropriate to disregard any
  relevant evidence on any issue in any case, patent
  cases included. Thus evidence rising out of the
  so-called "secondary considerations" must always when
  <span CLASS="page_no" data-cite="102 uspq 2d 1771" data-cite-type="ReporterOfDecisions" data-cite-pageno="1771" data-primary-citation="102 U.S.P.Q.2d 1760">[**1771]</span> present be considered en route to a determination of
  obviousness. . . . Indeed, evidence of secondary
  considerations may often be the most probative and
  cogent evidence in the record. It may often establish
  that an invention
<span CLASS="page_no" data-cite="676 f 3d 1076" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1076" data-primary-citation="676 F.3d 1063">[*1076]</span> 
  appearing to have been
  obvious in light of the prior art was not. It is to be
  considered as part of all the evidence, not just when
  the decisionmaker remains in doubt after reviewing the
  art.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3UPG1?jcsearch=713%20f%202d%201530&amp;summary=yes#jcite">713 F.2d 1530</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3UPG1?jcsearch=713%20f%202d%201530&amp;summary=yes#jcite">1538-39</a> (Fed. Cir. 1983) (citations omitted). Many
subsequent cases have expressly followed <i>Stratoflex's</i>
directive that courts consider all objective evidence before
reaching an obviousness conclusion. <i>See Ruiz v. A.B. Chance</i>
<i>Co.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X2PO8N?jcsearch=234%20f%203d%20654&amp;summary=yes#jcite">234 F.3d 654</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X2PO8N?jcsearch=234%20f%203d%20654&amp;summary=yes#jcite">663</a> (Fed. Cir. 2000) ("Our precedent
clearly establishes that the district court must make
<i>Graham</i> findings before invalidating a patent for
obviousness."); <i>Cable Elec. Prods, v. Genmark, Inc.</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XABRF9?jcsearch=770%20f%202d%201015&amp;summary=yes#jcite">770 F.2d 1015</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XABRF9?jcsearch=770%20f%202d%201015&amp;summary=yes#jcite">1026</a> (Fed. Cir. 1985) (quoting
<i>Stratoflex</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3UPG1?jcsearch=713%20f%202d%201530&amp;summary=yes#jcite">713 F.2d at 1539</a>) ("The opinions of this
court have suggested that evidence on these secondary
considerations is to be taken into account <i>always</i>,
`not just when the decisionmaker remains in doubt after
reviewing the art.'"); <i>Simmons Fastener Corp. v. Illinois</i>
<i>Tool Works, Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3J69G?jcsearch=739%20f%202d%201573&amp;summary=yes#jcite">739 F.2d 1573</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3J69G?jcsearch=739%20f%202d%201573&amp;summary=yes#jcite">1575</a> (Fed. Cir. 1984);
("The <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=35%20U.S.C.%20%20103&amp;summary=yes#jcite">section 103</a> test of nonobviousness set forth in
<i>Graham</i> is a four part inquiry comprising, not only the
three familiar elements (scope and content of the prior
art, differences between the prior art and the claims at issue, and
level of ordinary skill in the pertinent art), but also
evidence of secondary considerations when such evidence is, of
course, present"); <i>Richardson-Vicks Inc. v. Upjohn</i>
<i>Co.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X36F9U?jcsearch=122%20f%203d%201476&amp;summary=yes#jcite">122 F.3d 1476</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X36F9U?jcsearch=122%20f%203d%201476&amp;summary=yes#jcite">1483</a> (Fed. Cir. 1997) (holding that "we
must consider all of the evidence under the <i>Graham</i>
factors before reaching our decision"); <i>Rockwell Int'l</i>
<i>Corp. v. United States</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X37O9L?jcsearch=147%20f%203d%201358&amp;summary=yes#jcite">147 F.3d 1358</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X37O9L?jcsearch=147%20f%203d%201358&amp;summary=yes#jcite">1366</a> (Fed. Cir. 1998)
(following <i>Richardson-Vicks</i>); and <i>Kan. Jack, Inc.</i>
<i>v. Kuhn</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X46152?jcsearch=719%20f%202d%201144&amp;summary=yes#jcite">719 F.2d 1144</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X46152?jcsearch=719%20f%202d%201144&amp;summary=yes#jcite">1150-51</a> (Fed. Cir. 1983) (finding
that a district court's consideration of commercial success
complied with "the basic requirement that <i>all</i> evidence
touching the obvious-nonobvious issue be fully considered
before a conclusion is reached on that issue" (citing <i>In re</i>
<i>Sernaker</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XABNDD?jcsearch=702%20f%202d%20989&amp;summary=yes#jcite">702 F.2d 989</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XABNDD?jcsearch=702%20f%202d%20989&amp;summary=yes#jcite">996</a> (Fed. Cir. 1983))).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While many panels of this court have adhered to
<i>Stratoflex's</i> directive, some instead have spoken of
the obviousness analysis in terms of a "prima facie" case which
must then be "rebutted" by the patentee. Under that framework,
a court inquires whether the party challenging validity has
proven a "prima facie" case of obviousness, based only on
reference to the patent and <span CLASS="page_no" data-cite="2012 bl 92043 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[***13]</span> the proffered prior art, and only
then considers objective evidence, asking whether such evidence
is sufficient to <i>overcome</i> the prima facie case.<a HREF="#fn300" name="fnref_fn300">[fn3]</a>
<span CLASS="page_no" data-cite="676 f 3d 1077" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1077" data-primary-citation="676 F.3d 1063">[*1077]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Despite this language, however, those cases should not be
interpreted as establishing a formal burden-shifting framework.
This is so for a number of reasons. First, a review of those
cases indicates that in none was the placement of the burden
with respect to evidence of objective considerations, or the
timing of the fact finder's consideration of that evidence,
determinative. <i>See <cite>supra</cite></i> n. 3.
<span CLASS="page_no" data-cite="102 uspq 2d 1772" data-cite-type="ReporterOfDecisions" data-cite-pageno="1772" data-primary-citation="102 U.S.P.Q.2d 1760">[**1772]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, even panels that have used the "prima facie" and
"rebuttal" language generally have made clear that a fact
finder must consider <i>all</i> evidence of obviousness and
nonobviousness before reaching a determination. For example, in
<i>Iron Grip Barbell Co. v. USA Sports, Inc.</i>, while the
panel did hold that "there is no objective evidence to rebut
the strong showing of obviousness based on the prior art,"
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XGA31H?jcsearch=392%20f%203d%201317&amp;summary=yes#jcite">392 F.3d 1317</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XGA31H?jcsearch=392%20f%203d%201317&amp;summary=yes#jcite">1325</a> (Fed. Cir. 2004), it also cautioned that, in
"determining the question of obviousness, inquiry should always
be made into whatever objective evidence of nonobviousness
there may be." <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XGA31H?jcsearch=392%20F.3d%201317&amp;summary=yes#jcite">Id. at 1323</a> (quoting <i>Vandenberg v.</i>
<i>Dairy Equip. Co.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X437VM?jcsearch=740%20f%202d%201560&amp;summary=yes#jcite">740 F.2d 1560</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X437VM?jcsearch=740%20f%202d%201560&amp;summary=yes#jcite">1567</a> (Fed. Cir. 1984)). In
<i>Transocean Offshore Deepwater Drilling, Inc. v. Maersk</i>
<i>Contractors USA, Inc.</i>, while the panel observed that,
"[i]f all of the factual disputes regarding the objective
evidence resolve in favor of [plaintiff], it has presented a
strong basis for rebutting the <i>prima facie</i> case [of
obviousness]," the panel stated, "[t]o be clear, a district
court must <i>always</i> consider any objective evidence of
nonobviousness presented in a case." <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1E2RA2003?jcsearch=617%20f%203d%201296&amp;summary=yes#jcite">617 F.3d 1296</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1E2RA2003?jcsearch=617%20f%203d%201296&amp;summary=yes#jcite">1305</a>
(Fed. Cir. 2010). And in <i>WMS Gaming Inc. v. International</i>
<i>Game Technology</i>, while the panel stated that "[t]he
objective evidence of nonobviousness may be used to rebut a
prima facie case of obviousness based on prior art references,"
it also stated that "[t]he consideration of the objective
evidence presented by the patentee is a necessary part of the
obviousness determination." <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X36AV9?jcsearch=184%20f%203d%201339&amp;summary=yes#jcite">184 F.3d 1339</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X36AV9?jcsearch=184%20f%203d%201339&amp;summary=yes#jcite">1359</a> (Fed. Cir. 1999).
Thus, a reading of these cases that permits a fact finder to
reach a conclusion of obviousness before considering all
relevant evidence, including evidence of objective
considerations, would not only conflict with
<i>Stratoflex's</i> directive that objective considerations
are "to be considered as part of all the evidence, not just
when the decision-maker remains in doubt after reviewing the
art," <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3UPG1?jcsearch=713%20f%202d%201530&amp;summary=yes#jcite">713 F.2d at 1538</a>, but would ignore their actual holdings.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Next, the Supreme Court has never imposed nor even contemplated
a formal burden-shifting framework in the patent litigation
context.<a HREF="#fn400" name="fnref_fn400">[fn4]</a> It has, instead, required
<span CLASS="page_no" data-cite="676 f 3d 1078" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1078" data-primary-citation="676 F.3d 1063">[*1078]</span> 
that all evidence relevant to obviousness or nonobviousness
be considered, and be considered collectively. In
<i>Graham</i>, the Court stated that "[s]uch secondary
considerations as commercial success, long felt but unsolved
needs, failure of others, etc., might be utilized to give light
to the circumstances surrounding the origin of the subject
matter sought to be patented," along with the scope and content
of the prior art, the differences between the prior art and the
claims at issue, and the level <span CLASS="page_no" data-cite="2012 bl 92043 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[***14]</span> of ordinary skill in the
pertinent art. <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">383 U.S. at 17-18</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=86%20supreme%20court%20684&amp;summary=yes#jcite">86 S.Ct. 684</a>. Notably, the
Court did not characterize the objective factors as
after-the-fact considerations or relegate them to "secondary
status." The Court, rather, indicated that the objective
considerations have broader applicability, noting that, "[a]s
indicia of obviousness or nonobviousness, these inquiries may
have relevancy." <i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=383%20U.S.%20at%2017-18&amp;summary=yes#jcite">Id</a>.</i> The Court recently reaffirmed
this approach to objective considerations when it described the
obviousness inquiry as "expansive and flexible" and noted that
<i>Graham</i> "invite[s] the courts, where appropriate, to
look at any secondary considerations that would prove
instructive." <i>KSR</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. at 415</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>.
And, in 141 the Court reaffirmed both the <span CLASS="page_no" data-cite="102 uspq 2d 1773" data-cite-type="ReporterOfDecisions" data-cite-pageno="1773" data-primary-citation="102 U.S.P.Q.2d 1760">[**1773]</span> scope and
placement of the burden of proof in these circumstances.
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">131 S.Ct. at 2245</a> n. 4.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In 141 the Court was asked to articulate the standard
of proof a party must satisfy to prove an invalidity defense.
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">131 S.Ct. at 2242</a>. The Court held that the standard of proof is
proof by clear and convincing evidence. <i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FI916003?jcsearch=131%20S.%20Ct.%20at%202242&amp;summary=yes#jcite">Id</a>.</i> In
explaining that holding, the Court differentiated between the
concepts of burden of proof, burden of production, burden of
persuasion, and standard of proof. <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FI916003?jcsearch=131%20S.%20Ct.%20at%202242&amp;summary=yes#jcite">Id. at 2245</a>. As the
Court explained, the commonly used term "burden of proof
encompasses the concepts of "burden of persuasion" and "burden
of production." <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FI916003?jcsearch=131%20S.%20Ct.%20at%202242&amp;summary=yes#jcite">Id. at 2245</a> n. 4. The burden of
persuasion specifies "which party loses if the evidence is
balanced," while the burden of production specifies "which
party must come forward with evidence at various stages in the
litigation." <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FI916003?jcsearch=131%20S.%20Ct.%20at%202242&amp;summary=yes#jcite">Id. at 2245</a> n. 4. The standard of proof,
the court further explained, specifies "how difficult it will
be for the party bearing the burden of persuasion to convince
the jury of the facts in its favor." <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FI916003?jcsearch=131%20S.%20Ct.%20at%202242&amp;summary=yes#jcite">Id. at 2245</a> n. 4.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Court resorted to common-law principles to determine that
the standard of proof is proof by clear and convincing evidence
because the Patent Act does not explicitly articulate the
standard of proof. <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FI916003?jcsearch=131%20S.%20Ct.%20at%202242&amp;summary=yes#jcite">Id. at 2245-46</a>. By contrast, the
Court noted, the Patent Act specifies that the burden of proof
is placed on the party challenging validity: "The burden of
establishing invalidity of a patent or any claim thereof shall
rest on the party asserting such invalidity." <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FI916003?jcsearch=131%20S.%20Ct.%20at%202242&amp;summary=yes#jcite">Id.
at 2245</a> (quoting <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEJ050003?jcsearch=35%20usc%20282&amp;summary=yes#jcite">35 U.S.C. &sect; 282</a>). The Court provided no
indication that it believes the burden of persuasion should
shift to the patentee at some point to prove
nonobviousness.<a HREF="#fn500" name="fnref_fn500">[fn5]</a>
<span CLASS="page_no" data-cite="676 f 3d 1079" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1079" data-primary-citation="676 F.3d 1063">[*1079]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, not only is <i>Stratoflex</i> the law, it is sound
in requiring that a fact finder consider the objective evidence
before reaching an obviousness determination. The objective
considerations, when considered with the balance of the
obviousness evidence in the record, guard as a check against
hindsight bias. <i>Graham</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">383 U.S. at 36</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=86%20supreme%20court%20684&amp;summary=yes#jcite">86 S.Ct. 684</a>
(quoting <i>Monroe Auto Equip. Co. v. Heckethorn Mfg.</i>
<i>&amp; Supply Co.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3LPPU?jcsearch=332%20f%202d%20406&amp;summary=yes#jcite">332 F.2d 406</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3LPPU?jcsearch=332%20f%202d%20406&amp;summary=yes#jcite">412</a> (6th Cir. 1964)). In
<i>Graham</i>, the Court recognized the danger of hindsight
bias and the ameliorative effect that the objective
considerations might offer. In discussing the utility of the
objective considerations, the Court cited a law review note
published after the nonobviousness requirement was enacted in
the 1952 Patent Act. <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=383%20U.S.%201&amp;summary=yes#jcite">Id. at 18</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=86%20supreme%20court%20684&amp;summary=yes#jcite">86 S.Ct. 684</a> (citing
Richard L. Robbins, <i>Subtests of "Nonobviousness": A</i>
<i>Nontechnical Approach to Patent <span CLASS="page_no" data-cite="2012 bl 92043 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[***15]</span> Validity</i>,
112 U. Pa. L. Rev. 1169 (1964) ("Robbins")). In that note, the author
argued that the instruments of decision-making applied in
patent cases at the time were inadequate and allowed judges to
rely on "judicial hunches," thereby deciding cases on
extralegal grounds. Robbins, 112 U. Pa. L. Rev. at 1170 &amp;
n. 11 (citing Joseph C. Hutcheson, Jr., <i>The Judgment</i>
<i>Intuitive: The Function of the "Hunch" in Judicial</i>
<i>Decisions</i>, 14 Cornell L.Q. 274, 278 (1929)). Such
"judicial hunches" are encouraged by hind-sight bias. As one
commentator recently observed, "decision-makers unconsciously
let knowledge of the invention bias their conclusion concerning
whether the invention was obvious in the first instance."
Gregory N. Mandel, <i>Patently Non-Obvious: Empirical</i>
<i>Demonstration that the Hindsight Bias Renders Patent Decisions</i>
<i>Irrational</i>, 67 Ohio St. L.J. 1391, 1393 (2006). In other
words, knowing that the inventor succeeded in making the
patented invention, a fact finder might develop a hunch that
the claimed invention was obvious, and then construct a
selective version of the facts that confirms that hunch. This
is precisely why the Supreme Court explained that objective
considerations might prevent a fact finder from falling into
such a trap, observing that objective considerations might
serve to "resist the temptation to read into the prior art the
teachings of the invention in issue." <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">383 U.S. at 36</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C6EI?jcsearch=86%20supreme%20court%20684&amp;summary=yes#jcite">86 S.Ct. 684</a>.<a HREF="#fn600" name="fnref_fn600">[fn6]</a> And, it is precisely why <span CLASS="page_no" data-cite="102 uspq 2d 1774" data-cite-type="ReporterOfDecisions" data-cite-pageno="1774" data-primary-citation="102 U.S.P.Q.2d 1760">[**1774]</span> fact finders must withhold
judgment on an obviousness challenge until it considers all
relevant evidence, including that relating to the objective
considerations.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In sum, opinions of this court should not be read to require a
burden-shifting framework in derogation of
<i>Stratoflex</i>'s directive that objective evidence be
considered before making an obviousness determination and in
disregard of where the burdens of proof and persuasion are
properly
<span CLASS="page_no" data-cite="676 f 3d 1080" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1080" data-primary-citation="676 F.3d 1063">[*1080]</span> 
placed in district court litigation.<a HREF="#fn700" name="fnref_fn700">[fn7]</a> Such a reading
disregards our own precedent and is inconsistent with Supreme
Court case law, including very recent case law.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   3.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court appears to have fallen into the
understandable but improper trap of constructing a selective
version of the facts relating to the objective considerations
so as to confirm its hunch that the asserted claims were
obvious. The district court focused on objective evidence that
supported its obviousness determination, but ignored other
evidence that cast the objective considerations in a light
favorable to Cephalon. And, it is clear that the district court
assumed that it was Cephalon's burden to disprove the court's
initial obviousness finding.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Had the district court, instead, considered the objective
evidence in its entirety before making an obviousness finding,
and considered that evidence in light of the actual burden
imposed upon a patentee and a patent challenger, much of that
evidence would have encouraged the district court to question
the claim that the mere existence of an immediate-release
formulation of cyclobenzaprine made an extended-release version
of that drug obvious. Specifically, <span CLASS="page_no" data-cite="2012 bl 92043 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[***16]</span> we find that evidence of a
longfelt need for an extended-release formulation and the
failure of others to formulate one strongly support a
conclusion of nonobviousness. We address each of these
considerations.<a HREF="#fn800" name="fnref_fn800">[fn8]</a>
<span CLASS="page_no" data-cite="676 f 3d 1081" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1081" data-primary-citation="676 F.3d 1063">[*1081]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <span CLASS="page_no" data-cite="102 uspq 2d 1775" data-cite-type="ReporterOfDecisions" data-cite-pageno="1775" data-primary-citation="102 U.S.P.Q.2d 1760">[**1775]</span> a.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Cephalon claims that another pharmaceutical company, ALZA,
tried but failed to develop an extended-release cyclobenzaprine
formulation.<a HREF="#fn900" name="fnref_fn900">[fn9]</a> The district court rejected this claim,
because, in its view, ALZA's goals were different than
Cephalon's. Mylan and Par endorse the district court's
reasoning. The district court, however, ignored the fact that
Cephalon and ALZA shared a common goal: to make a
therapeutically effective product. This was clear error.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Evidence that others tried but failed to develop a claimed
invention may carry significant weight in an obviousness
inquiry. "While absolute certainty is not necessary to
establish a reasonable expectation of success, there can be
little better evidence negating an expectation of success than
actual reports of failure." <i>Boehringer Ingelheim Vetmedica,</i>
<i>Inc. v. Schering-Plough Corp.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XADUSB?jcsearch=320%20f%203d%201339&amp;summary=yes#jcite">320 F.3d 1339</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XADUSB?jcsearch=320%20f%203d%201339&amp;summary=yes#jcite">1354</a>
(Fed. Cir. 2003). This is particularly true when the evidence
indicates that others found development of the claimed
invention difficult and failed to achieve any success.
<i>Advanced Display Sys. v. Kent State Univ.</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3IR52?jcsearch=212%20f%203d%201272&amp;summary=yes#jcite">212 F.3d 1272</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3IR52?jcsearch=212%20f%203d%201272&amp;summary=yes#jcite">1285</a> (Fed. Cir. 2000). In such circumstances, "evidence of
failed attempts by others could be determinative on the issue
of obviousness." <i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3IR52?jcsearch=212%20F.3d%201272&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span id="headnote_ref_pq2-dec_914854">[6]</span> The evidence of ALZA's failure to develop an extended-release
formulation strongly supports a nonobviousness finding. In the
late 1990s, ALZA performed pharmacokinetic modeling and created
a PK profile for immediate-release cyclobenzaprine dosed three
times a day. This approach was similar to the manner in which
Drs. Venkatesh and Clevenger modeled their PK profile. The
immediate-release PK profile that ALZA modeled represented
"peaks and valleys" on a graph, with blood plasma
concentrations undulating as time passed. ALZA then
hypothesized a PK profile for an extended-release
cyclobenzaprine product based on its model for the
immediate-release product. For its extended-release PK profile,
ALZA chose a straight line that cut through the
immediate-release profile, staying below the peaks and above
the valleys. ALZA hoped that staying below the peaks would
avoid side effects and that staying above the valleys would
maintain therapeutic effectiveness. Clinical trials, however,
revealed that ALZA's product was not therapeutically effective.
ALZA lost $10 million in its unsuccessful attempt to develop an
extended-release formulation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  At trial, Cephalon called a former ALZA vice president, Dr.
Samuel Saks. Cephalon's counsel showed Dr. Saks Cephalon's PK
profile. That profile indicated that Cephalon had departed from
ALZA's attempt
<span CLASS="page_no" data-cite="676 f 3d 1082" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1082" data-primary-citation="676 F.3d 1063">[*1082]</span> 
to cut through the immediate release PK profile's peaks and
valleys. Rather, Cephalon had chosen a PK profile in which the
Cmax rose higher and the minimum blood plasma
concentration (Cmin) dipped lower than those of the
immediate-release profile. After reviewing Cephalon's PK
profile, Dr. Saks <span CLASS="page_no" data-cite="2012 bl 92043 p 17" data-cite-type="Bloomberg" data-cite-pageno="17" data-primary-citation="">[***17]</span> expressed surprise that Cephalon succeeded,
because he believed a lower Cmin would be less
effective. Thus, where ALZA failed to develop a therapeutically
effective product, Cephalon took a materially different
approach and succeeded. Evidence that others were "`going in
different ways' is strong evidence that the [inventor's] way
would not have been obvious." <i>Panduit Corp. v. Dennison</i>
<i>Mfg. Co.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X4A9D8?jcsearch=774%20f%202d%201082&amp;summary=yes#jcite">774 F.2d 1082</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X4A9D8?jcsearch=774%20f%202d%201082&amp;summary=yes#jcite">1099</a> (Fed. Cir. 1985), <i>vacated</i>
<i>and remanded on other grounds</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CB80?jcsearch=475%20us%20809&amp;summary=yes#jcite">475 U.S. 809</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CB80?jcsearch=106%20supreme%20court%201578&amp;summary=yes#jcite">106 S.Ct. 1578</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CB80?jcsearch=89%20l%20ed%202d%20817&amp;summary=yes#jcite">89 L.Ed.2d 817</a> (1986).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court disregarded ALZA's failures. ALZA intended
to make a formulation that was not only therapeutically
effective, but one that also reduced side effects. Cephalon's
patents do not cover a formulation that reduces side effects.
The district court noted that an alleged failure must be
directed to the problem that a patent purports to solve.
<i>Symbol Techs., Inc. v. Opticon, Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X30HGC?jcsearch=935%20f%202d%201569&amp;summary=yes#jcite">935 F.2d 1569</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X30HGC?jcsearch=935%20f%202d%201569&amp;summary=yes#jcite">1578</a> (Fed. Cir. 1991). Because ALZA had the additional goal of
reducing side effects, the district court believed that ALZA's
failure was not directed to the problem that Cephalon's patents
purport to solve.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court clearly erred because it disregarded that
Cephalon and ALZA did <span CLASS="page_no" data-cite="102 uspq 2d 1776" data-cite-type="ReporterOfDecisions" data-cite-pageno="1776" data-primary-citation="102 U.S.P.Q.2d 1760">[**1776]</span> share a central common goal: to create a
therapeutically effective product. There is no dispute that
ALZA sought to create a product that worked. The patents in
suit, of course, cover a therapeutically effective PK profile.
The district court was not required to disregard Cephalon and
ALZA's common goal simply because ALZA had an
<i>additional</i> goal not encompassed by the patents in
suit. The purpose of evidence of failure of others is to show
"indirectly the presence of a significant defect in the prior
art, while serving as a simulated laboratory test of the
obviousness of the solution to a skilled artisan." <i>Symbol</i>
<i>Techs.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X30HGC?jcsearch=935%20f%202d%201569&amp;summary=yes#jcite">935 F.2d at 1578-79</a> (quoting Robbins,
112 U. Pa. L. Rev. at 1173). ALZA's failure accomplishes that purpose,
confirming that a therapeutically effective PK profile was
lacking in the prior art and that skilled artisans struggled to
attain it. Such a scenario is classic evidence of
nonobviousness. <i>See, e.g., Advanced Display Sys.</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3IR52?jcsearch=212%20f%203d%201272&amp;summary=yes#jcite">212 F.3d at 1285</a> (holding that the objective evidence supported an
obviousness finding where others had "tried for a long time" to
develop the claimed invention but found it "very hard" and
"were all not successful"). ALZA's failure to develop a
therapeutically effective product, in sum, is keyed to the
problem that the patents in suit purport to solve, and it
supports a finding that Cephalon's accomplishment was not
obvious to those skilled in the art.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   b.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Cephalon also claimed that a longfelt need existed for an
extended-release cyclobenzaprine formulation and that Amrix
satisfied that need. The district court rejected that argument
because it believed Cephalon failed to offer any expert
testimony to support it. The district court's assessment of
this factor was inadequate.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Longfelt need is closely related to the failure of others.
Evidence is particularly probative of obviousness when it
demonstrates both that a demand existed for the patented
invention, and that others tried but failed to satisfy that
demand. <span CLASS="page_no" data-cite="2012 bl 92043 p 18" data-cite-type="Bloomberg" data-cite-pageno="18" data-primary-citation="">[***18]</span> <i>See, e.g., In re Piasecki</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3J8CE?jcsearch=745%20f%202d%201468&amp;summary=yes#jcite">745 F.2d 1468</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3J8CE?jcsearch=745%20f%202d%201468&amp;summary=yes#jcite">1475</a>
(Fed. Cir. 1984) (finding nonobviousness where the evidence
demonstrated a
<span CLASS="page_no" data-cite="676 f 3d 1083" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1083" data-primary-citation="676 F.3d 1063">[*1083]</span> 
failure of others to provide a feasible solution to a
longstanding problem); <i>Alco Standard Corp. v. Tenn. Valley</i>
<i>Auth.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3I41O?jcsearch=808%20f%202d%201490&amp;summary=yes#jcite">808 F.2d 1490</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3I41O?jcsearch=808%20f%202d%201490&amp;summary=yes#jcite">1500</a> (Fed. Cir. 1986) (affirming a
nonobviousness finding where the evidence showed that the
relevant industry had searched for more than a decade for a
reliable solution and that major manufacturers in the industry
had tried but failed to develop such a solution).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Cephalon's proof indicates that a long-felt need existed for a
therapeutically effective, extended-release cyclobenzaprine
formulation. The immediate-release formulation existed for
decades, but that formulation's regimen of multiple daily doses
led to poor patient compliance. As discussed above, moreover,
others tried but failed to develop an extended-release version.
In addition to these facts, Cephalon called Dr. David Steiner,
a physician who has practiced in pain management for more than
a decade. Dr. Steiner discussed his experiences treating his
patients' pain in the clinic. He testified that patient
compliance with a medical regimen is important and that he
began prescribing Amrix, in part, because of the prospect of
more convenient dosing for his patients.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Not only was the district court wrong that Cephalon produced no
expert testimony on this issue, but the district court was
wrong to ignore the non-expert evidence proffered on this
point. In combination with compelling evidence of the failure
of others to produce an extended-release formulation, this
factor further supports a nonobviousness finding.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   4.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Where, as here, the obviousness determination turns on whether
one of ordinary skill in the art would have expected that a
particular formulation of an extended-release drug would be
successful &mdash; in other words, would render a
therapeutically effective treatment &mdash; objective indicia
of failure of others and longfelt need are particularly
telling. The district court would have encountered a different
landscape had it examined the objective evidence in light of
the absence of a known PK/PD relationship. ALZA's failure to
develop a therapeutically effective, extended-release
formulation suggests that skilled artisans would not have
reasonably expected to succeed in developing the claimed
formulation. The long delay between the marketing of an
immediate-release formulation and Amrix, and Dr. Steiner's
testimony of longfelt need, moreover, supports the inference
that it was difficult for researchers to create a
therapeutically effective, extended-release product. Because a
desire existed for such a product, researchers, <span CLASS="page_no" data-cite="102 uspq 2d 1777" data-cite-type="ReporterOfDecisions" data-cite-pageno="1777" data-primary-citation="102 U.S.P.Q.2d 1760">[**1777]</span> presumably,
would have created one if they were able to do so.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Rather than supporting a finding of obviousness, the most
relevant objective considerations, when considered as part of
the totality of the evidence, support a nonobviousness finding.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   D.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span id="headnote_ref_pq2-dec_914856">[8]</span> The record, in sum, is insufficient to support a conclusion of
obviousness by clear and convincing evidence. At its core,
Mylan and Par's proof of obviousness <span CLASS="page_no" data-cite="2012 bl 92043 p 19" data-cite-type="Bloomberg" data-cite-pageno="19" data-primary-citation="">[***19]</span> is that the claimed PK
profile is bioequivalent to the immediate-release profile. In
rejecting the sufficiency of Mylan and Par's proof, we do not
hold that bioequivalence can never serve as evidence of
obviousness. Indeed, it is most certainly relevant to that
inquiry. We only hold that, on the facts of this case &mdash;
in which therapeutic effectiveness is a claimed limitation and
the parties do not dispute that cyclobenzaprine lacked a known
PK/PD relationship &mdash; Mylan and Par cannot rely on
bioequivalence as the sole basis for an obviousness finding,
particularly given the
<span CLASS="page_no" data-cite="676 f 3d 1084" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1084" data-primary-citation="676 F.3d 1063">[*1084]</span> 
heavy burden of proof imposed on them in this context.
Indeed, defense counsel acknowledged at oral argument that
Mylan and Par are not requesting a categorical rule that it is
always obvious to try to target bioequivalence when formulating
an extended-release formulation. <i>See</i> Oral Argument
at 8:54, <i>available at</i>
http://www.cafc.uscourts.gov/oral-argument-recordings/
2011-1399/all. If we were to affirm the district court's
obviousness ruling on the basis of this record, we
effectively would announce such a rule.<a HREF="#fn1000" name="fnref_fn1000">[fn10]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court erred in finding that Mylan and Par proved
that the asserted claims are obvious by clear and convincing
evidence.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   IV.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We address next Mylan and Par's best mode defense. The district
court rejected Mylan and Par's claim that the patents in suit
are invalid for failure to disclose the best mode. Although the
district court applied the incorrect test for a best mode
disclosure violation, the district court's findings support its
ultimate conclusion that no best mode disclosure violation
existed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A patent's specification must "set forth the best mode
contemplated by the inventor of carrying out his invention."
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEIVVO003?jcsearch=35%20usc%20112&amp;summary=yes#jcite">35 U.S.C. &sect; 112</a> &para; 1 (2006). The version of the Patent Act
currently in effect provides that, although an applicant must
disclose the best mode to register a patent, a party to a
lawsuit may not rely on an alleged best mode disclosure
violation to cancel, invalidate, or hold a patent otherwise
unenforceable. <i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEIVVO003?jcsearch=35%20U.S.C.%20%20112&amp;summary=yes#jcite">Id</a>.</i>; Leahy-Smith America Invents Act,
Pub.L. No. <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=USACTS%20112-29&amp;summary=yes#jcite">112-29</a>, sec. 15(a), <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=125%20stat%20284&amp;summary=yes#jcite">125 Stat. 284</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=125%20stat%20284&amp;summary=yes#jcite">328</a> (2011) (to be
codified at <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEJ050003?jcsearch=35%20U.S.C.%20%20282%20(3)(A)&amp;summary=yes#jcite">35 U.S.C. &sect; 282</a> &para; 2(3)(A)). That provision,
however, is inapplicable to this case because it is the product
of amendments made to the Patent Act that became effective
after this action was filed. Leahy-Smith America Invents Act,
Pub.L. No. <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=USACTS%20112-29&amp;summary=yes#jcite">112-29</a>, sec. 15(c), <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=125%20stat%20284&amp;summary=yes#jcite">125 Stat. 284</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/1?citation=125%20stat%20284&amp;summary=yes#jcite">328</a> (2011)
(providing that the best mode amendments apply only to actions
commenced on or after the effective date of the amendments).
The version of the Patent Act applicable to this case permits
an accused infringer to assert a best mode disclosure violation
as a defense. <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEJ050003?jcsearch=35%20U.S.C.%20%20282(3)&amp;summary=yes#jcite">35 U.S.C. &sect; 282</a> &para; 2(3) (2006).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A defense of failure to disclose the best mode is a question of
fact. <i>Zygo Corp. v. Wyko Corp.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X439RO?jcsearch=79%20f%203d%201563&amp;summary=yes#jcite">79 F.3d 1563</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X439RO?jcsearch=79%20f%203d%201563&amp;summary=yes#jcite">1566-67</a>
(Fed. Cir. 1996). We review a lower court's finding of no best
mode disclosure violation for clear error. <i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X439RO?jcsearch=79%20F.3d%201563&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mylan and Par claim that the specification fails to disclose
the best mode because it omits a particular range of dew
points. The claimed cyclobenzaprine formulation is made with a
coated bead. During the formulation process, the bead is placed
in a fluid bed machine, which sprays a layer of <span CLASS="page_no" data-cite="2012 bl 92043 p 20" data-cite-type="Bloomberg" data-cite-pageno="20" data-primary-citation="">[***20]</span> the drug and a
layer of extended-release coating on the bead. The dew point of
the
<span CLASS="page_no" data-cite="676 f 3d 1085" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1085" data-primary-citation="676 F.3d 1063">[*1085]</span> 
air entering the fluid bed must be controlled. Mylan and
Par claim that <span CLASS="page_no" data-cite="102 uspq 2d 1778" data-cite-type="ReporterOfDecisions" data-cite-pageno="1778" data-primary-citation="102 U.S.P.Q.2d 1760">[**1778]</span> Dr. Venkatesh preferred dew points of 6-12&deg;C
for immediate-release coating and 7-16&deg;C for
extended-release coating, with target dew points of 8&deg;C and
10&deg;C, respectively. The specification does not disclose
those dew points.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To determine whether a best mode disclosure violation exists, a
fact finder applies a two-prong test. First, the fact finder
determines whether, at the time the application was filed, the
inventor possessed a best mode for practicing the invention.
<i>Eli Lilly &amp; Co. v. Barr Labs., Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X50SKQ?jcsearch=251%20f%203d%20955&amp;summary=yes#jcite">251 F.3d 955</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X50SKQ?jcsearch=251%20f%203d%20955&amp;summary=yes#jcite">963</a> (Fed. Cir. 2001) (citations omitted). A subjective inquiry,
the first prong focuses on "the inventor's state of mind at the
time he filed the patent application, and asks whether the
inventor considered a particular mode of practicing the
invention to be superior to all other modes at the time of
filing." <i>Teleflex, Inc. v. Ficosa N. Am. Corp.</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XFL2AO?jcsearch=299%20f%203d%201313&amp;summary=yes#jcite">299 F.3d 1313</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XFL2AO?jcsearch=299%20f%203d%201313&amp;summary=yes#jcite">1330</a> (Fed. Cir. 2002) (citation omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court found that Dr. Venkatesh preferred
particular dew points at the time the applications were filed.
In March 2003, before the patent applications were filed, Dr.
Venkatesh told the FDA that, during scale-up experiments, "the
dew point of the incoming air was monitored by setting the
control at a very low target of 8&deg;C (6-12)&deg;C" and that
"[diecreasing the dew point of the incoming process air
reduced the tackiness of the beads and reduced the tendency of
the coated beads from clumping together." Dr. Venkatesh
acknowledged that dew points could affect dissolution: "If you
don't use the proper optimization, then you may not get good
yield or you may not get the proper coating . . . [t]hen the
product will not be good. . . ." While Cephalon argued to the
district court that Dr. Venkatesh did not have a subjective
belief in a best mode, Cephalon does not contest on appeal the
district court's finding that he did have such a belief, and we
do not find that finding to have been clearly erroneous in any
event.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span id="headnote_ref_pq2-dec_914857">[9]</span> If the inventor possessed a best mode at the time of filing, as
the district court found Dr. Venkatesh did, the second prong of
the inquiry requires the fact finder to determine whether the
specification discloses sufficient information such that one
reasonably skilled in the art could practice the best mode.
<i>Eli Lilly</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X50SKQ?jcsearch=251%20f%203d%20955&amp;summary=yes#jcite">251 F.3d at 963</a> (citations omitted).
Because the second prong focuses on what the specification
teaches to a person of ordinary skill in the art, the inquiry
is objective. <i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X50SKQ?jcsearch=251%20F.3d%20at%20963&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mylan and Par mistakenly attempt to cast the second prong as an
inquiry concerning whether Dr. Venkatesh "concealed" his best
mode. Defs.' Resp. &amp; Reply Br. 50. That characterization is
inaccurate. Concealment implicates an inventor's state of mind,
which is inconsistent with an objective inquiry focused on what
the specification teaches to a skilled artisan. <i>U.S. Gypsum</i>
<i>Co. v. Nat'l Gypsum Co.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3MNN7?jcsearch=74%20f%203d%201209&amp;summary=yes#jcite">74 F.3d 1209</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3MNN7?jcsearch=74%20f%203d%201209&amp;summary=yes#jcite">1215-16</a>
(Fed. Cir. 1996). As we explained in <i>U.S. Gypsum</i>, this
court has used the term "concealment" as a shorthand way of
inquiring about the adequacy of the disclosure:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The "concealment" language of our case law originated
  <span CLASS="page_no" data-cite="2012 bl 92043 p 21" data-cite-type="Bloomberg" data-cite-pageno="21" data-primary-citation="">[***21]</span> in <i>In re Gay</i>, [<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XIDPKB?jcsearch=309%20F.2d%20769&amp;summary=yes#jcite">50 CCPA 725</a>] <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XIDPKB?jcsearch=309%20f%202d%20769&amp;summary=yes#jcite">309 F.2d 769</a>
  (CCPA 1962). In <i>Gay</i>, the Court of Customs and
  Patent Appeals (CCPA) explained that "the sole purpose
  of [the best mode] requirement is to restrain
  inventors from applying for patents while at the same
  time concealing from the public preferred embodiments
  of their inventions which they have in fact
  conceived." . . . Subsequently, the CCPA clarified
  that "only evidence of concealment (whether accidental
<span CLASS="page_no" data-cite="676 f 3d 1086" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1086" data-primary-citation="676 F.3d 1063">[*1086]</span> 
  or intentional) is to be considered. That
  evidence, in order to result in affirmance of a best
  mode rejection, must tend to show that the
  <i>quality</i> of an applicant's best mode
  disclosure is so poor as to effectively result in
  concealment." <i>In re Sherwood</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XIH323?jcsearch=613%20f%202d%20809&amp;summary=yes#jcite">613 F.2d 809</a>,
  <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XIH323?jcsearch=613%20f%202d%20809&amp;summary=yes#jcite">816</a> (CCPA 1980).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3MNN7?jcsearch=74%20F.3d%201209&amp;summary=yes#jcite">Id</a>.</i> Thus, the proper inquiry focuses on the adequacy
of the disclosure rather than motivation for any nondisclosure.
<i>See also Bayer AG v. Schein Pharms., Inc.</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XE4PNL?jcsearch=301%20f%203d%201306&amp;summary=yes#jcite">301 F.3d 1306</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XE4PNL?jcsearch=301%20f%203d%201306&amp;summary=yes#jcite">1320</a> (Fed. Cir. 2002) (explaining that the inquiry is
objective).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court did not directly address whether the
specification adequately disclosed the best mode. Rather, the
district court found that the dew points did not need to be
disclosed because they amounted to routine details. We have
recognized that routine details apparent to one of ordinary
skill in the art need not be disclosed to satisfy the best mode
disclosure requirement. <i>E.g., Teleflex</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XFL2AO?jcsearch=299%20f%203d%201313&amp;summary=yes#jcite">299 F.3d at 1331-32</a>; <i>Eli Lilly</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X50SKQ?jcsearch=251%20f%203d%20955&amp;summary=yes#jcite">251 F.3d at 963</a>; and <i>Young</i>
<i>Dental Mfg. Co. v. Q3 Special Prods., Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X4V1B2?jcsearch=112%20f%203d%201137&amp;summary=yes#jcite">112 F.3d 1137</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X4V1B2?jcsearch=112%20f%203d%201137&amp;summary=yes#jcite">1144</a> (Fed. Cir. 1997).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span CLASS="page_no" data-cite="102 uspq 2d 1779" data-cite-type="ReporterOfDecisions" data-cite-pageno="1779" data-primary-citation="102 U.S.P.Q.2d 1760">[**1779]</span> To conclude that the optimal dew points were routine details
exempt from disclosure, the district court was required to find
that the dew points would be apparent to a person of ordinary
skill in the art. <i>Teleflex</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XFL2AO?jcsearch=299%20f%203d%201313&amp;summary=yes#jcite">299 F.3d at 1331-32</a>. The
district court found the following: (1) it would be routine to
control humidity during product fabrication; (2) the allegedly
concealed dew points were within the normal operating range of
a commonly used fluid-bed coating device; (3) Dr. Venkatesh's
optimal dew point was within the normal operating range; and
(4) the defendants' own technicians were able to optimize the
dew point in just a few days. That evidence does not indicate
that the optimal dew points would actually be apparent to one
of ordinary skill in the art. If they were, the evidence,
presumably, would indicate that skilled artisans would know the
optimal dew points and program the fluid bed accordingly before
commencing production. The district court's findings indicate,
rather, that some, albeit minimal, work was required to
ascertain the optimal dew points.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span id="headnote_ref_pq2-dec_914858">[10]</span> Rather than finding that the dew points were routine details
apparent to one of ordinary skill in the art, the district
court could, and should, have made a more fundamental finding:
that the specification need not disclose the optimal dew points
to enable skilled artisans to practice the best mode. <i>See</i>
<i>U.S. Gypsum</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3MNN7?jcsearch=74%20f%203d%201209&amp;summary=yes#jcite">74 F.3d at 1215-16</a> (focusing the inquiry on
the adequacy of the disclosure). As one expert, Dr. Robert
Williams, explained, skilled artisans do not begin the
fabrication process by attempting to attain a particular dew
point in the fluid bed. Rather, they attempt to manipulate and
harmonize a number of parameters, including, for example, air
humidity, inlet air quantity, inlet <span CLASS="page_no" data-cite="2012 bl 92043 p 22" data-cite-type="Bloomberg" data-cite-pageno="22" data-primary-citation="">[***22]</span> air temperature, and spray
rate. Dew point is a function of the other parameters. The
totality of these parameters, when harmonized, creates the
optimal condition for fabricating product. Thus, as the
district court's findings suggest, skilled artisans would
expect to attain the optimal dew points during the ordinary
harmonization process by employing routine steps such as
controlling the humidity and operating the fluid bed within the
normal operating range. Because harmonization &mdash; a process
known to skilled artisans &mdash; would produce the optimal dew
points, the specification need not disclose them to enable
skilled artisans to practice the best mode. The disclosure is
adequate without them.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span id="headnote_ref_pq2-dec_914859">[11]</span> Mylan and Par argue that, because the dew points materially
affect the claimed invention, express disclosure in the
specification
<span CLASS="page_no" data-cite="676 f 3d 1087" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1087" data-primary-citation="676 F.3d 1063">[*1087]</span> 
was required. For this proposition, they cite
<i>Bayer</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XE4PNL?jcsearch=301%20f%203d%201306&amp;summary=yes#jcite">301 F.3d at 1312</a>. Mylan and Par misread
<i>Bayer.</i> There, we held that, to prove inadequate
disclosure of the best mode, an accused infringer must prove
that the undisclosed information affects the properties of the
claimed invention. <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XE4PNL?jcsearch=301%20F.3d%20at%201312&amp;summary=yes#jcite">Id. at 1319</a>. The panel also held
that an accused infringer may prove a best mode disclosure
violation if the undisclosed subject matter materially affects
the properties of the claimed invention, even if the
undisclosed subject matter is not strictly within the bounds of
the patent claims. <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XE4PNL?jcsearch=301%20F.3d%20at%201312&amp;summary=yes#jcite">Id. at 1316</a>. <i>Bayer</i> created
an exception to the general rule that "the best mode disclosure
requirement only refers to the invention defined by the
claims." <i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XE4PNL?jcsearch=301%20F.3d%20at%201312&amp;summary=yes#jcite">Id. at 1315-16</a>. <i>Bayer</i> is inapposite
here because there is no dispute that the dew points are within
the bounds of the asserted claims: The claims cover a
particular dissolution profile, and dew point affects
dissolution. The only issue here is whether the disclosure is
adequate to enable a person of ordinary skill in the art to
practice the invention incorporating the optimal dew points.
Mylan and Par cannot avoid that issue merely by claiming that
the dew points are material to the claimed invention.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Invalidation as a result of a best mode disclosure violation
requires proof by clear and convincing evidence.
<i>Teleflex</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XFL2AO?jcsearch=299%20f%203d%201313&amp;summary=yes#jcite">299 F.3d at 1330</a>. Mylan and Par cannot meet
that burden because the record indicates that skilled artisans
could readily obtain the optimal dew points using a common
fluid bed. We find, therefore, that the district court did not
err in rejecting Mylan and Par's best mode defense.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   V.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We address next Mylan's appeal in Case No. <cite>2011-1399</cite>. Mylan
appeals from the district court's order entering an injunction
against launch of its generic version of Amrix. Mylan argues
that it is virtually always improper to enjoin a prevailing
party from acting in a manner authorized by a district court's
own judgment; that it is particularly inappropriate to enter an
injunction pending appeal against a prevailing generic in an
ANDA action; and that, even if such an injunction is
permissible in the abstract, the district court <span CLASS="page_no" data-cite="102 uspq 2d 1780" data-cite-type="ReporterOfDecisions" data-cite-pageno="1780" data-primary-citation="102 U.S.P.Q.2d 1760">[**1780]</span> abused its
discretion when it entered an injunction in this case. Mylan
contends that it is entitled to recapture damages, <span CLASS="page_no" data-cite="2012 bl 92043 p 23" data-cite-type="Bloomberg" data-cite-pageno="23" data-primary-citation="">[***23]</span> capped by
the amount of the bond imposed, regardless of the outcome on
appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span id="headnote_ref_pq2-dec_914860">[12]</span> Given our ruling today, Mylan is no longer a prevailing party
or a prevailing generic, however. We have reversed the judgment
of invalidity upon which Mylan predicates its objections in
this appeal. If our resolution of the appeal in Case
No. <cite>2011-1409</cite> resulted in an order directing judgment in favor
of Cephalon and a permanent injunction, Mylan's own appeal
would certainly be moot. <i>See Grupo Mexicano de Desarrollo,</i>
<i>S.A. v. Alliance Bond Fund Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X2TJPJ?jcsearch=527%20us%20308&amp;summary=yes#jcite">527 U.S. 308</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X2TJPJ?jcsearch=527%20us%20308&amp;summary=yes#jcite">314</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X2TJPJ?jcsearch=119%20supreme%20court%201961&amp;summary=yes#jcite">119 S.Ct. 1961</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X2TJPJ?jcsearch=144%20l%20ed%202d%20319&amp;summary=yes#jcite">144 L.Ed.2d 319</a> (1999). In <i>Grupo Mexicano de</i>
<i>Desarrollo</i>, the Supreme Court explained:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  [I]f [a plaintiffs] lawsuit turns out to be
  meritorious &mdash; if he is found to be entitled to
  the permanent injunction that he seeks &mdash; even if
  the preliminary injunction was wrongly issued (because
  at that stage of the litigation the plaintiffs
  prospects of winning were not sufficiently clear, or
  the plaintiff was not suffering irreparable injury)
  its issuance would in any event be harmless error. The
  final injunction establishes that the defendant should
  not have been engaging in the conduct that was
  enjoined.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i></i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X2TJPJ?jcsearch=527%20U.S.%20308&amp;summary=yes#jcite">Id. at 314-15</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X2TJPJ?jcsearch=119%20supreme%20court%201961&amp;summary=yes#jcite">119 S.Ct. 1961</a>. <i>See also Global</i>
<i>NAPs, Inc. v. Verizon New England Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X173BL8003?jcsearch=489%20f%203d%2013&amp;summary=yes#jcite">489 F.3d 13</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X173BL8003?jcsearch=489%20f%203d%2013&amp;summary=yes#jcite">22</a>
(1st Cir. 2007)
<span CLASS="page_no" data-cite="676 f 3d 1088" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1088" data-primary-citation="676 F.3d 1063">[*1088]</span> 
("[A] party is wrongfully enjoined when it had a right all
along to do what it was enjoined from doing."); <i>Bhimenthal</i>
<i>v. Merrill Lynch, Pierce, Fenner &amp; Smith, Inc.</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X2O1T0?jcsearch=910%20f%202d%201049&amp;summary=yes#jcite">910 F.2d 1049</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X2O1T0?jcsearch=910%20f%202d%201049&amp;summary=yes#jcite">1054</a> (2d Cir. 1990) ("A party has been `wrongfully
enjoined' . . . if it is ultimately found that the enjoined
party had at all times the right to do the enjoined act.")
Thus, if Mylan was simply enjoined from engaging in conduct in
which it had no right to engage, Mylan's complaints about that
injunction become meaningless. This simple principle may or may
not ultimately apply in this case, however. It is unclear at
this stage what the ultimate resolution of this matter will be
and whether launch of Mylan's generic will be deemed
unauthorized. <i>See, e.g., Grupo Mexicano de Desarrollo</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X2TJPJ?jcsearch=527%20us%20308&amp;summary=yes#jcite">527 U.S. at 314-15</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X2TJPJ?jcsearch=119%20supreme%20court%201961&amp;summary=yes#jcite">119 S.Ct. 1961</a> (indicating that where a
permanent injunction either does not ultimately issue or is
narrower in scope than a preliminary injunction, a claim
against the bond could he).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Here, it is unclear whether a final judgment against Mylan will
be entered and, if so, what the scope of an injunctive remedy,
if any, might be. There is much litigation that is yet to occur
&mdash; both as to Cephalon's claims for relief and as to
Mylan's currently stayed counterclaims. For these reasons, we
find it premature to address Mylan's claim on the appeal bond
or to resolve the questions Mylan poses regarding the
circumstances under which, or the standards by which, an
injunction pending appeal may be imposed on a prevailing party
in an ANDA action. We dismiss Mylan's appeal without prejudice
to reassert a claim for damages against the appeal bond if and
when such a claim might be ripe and appropriate. In the
interim, the appeal bond will remain in place unless the
parties stipulate to its release.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   VI.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On a final matter, we note that, because Mylan's patent misuse
and antitrust claims remained unresolved at the time of appeal,
the parties did not appeal from a final judgment, which
normally precludes an appellate court <span CLASS="page_no" data-cite="2012 bl 92043 p 24" data-cite-type="Bloomberg" data-cite-pageno="24" data-primary-citation="">[***24]</span> from exercising
jurisdiction. <i>See</i> Fed.R.Civ.P. <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X144L48003?jcsearch=Fed.%20R.%20Civ.%20P.%2054&amp;summary=yes#jcite">54</a>. After the appeals
were filed, the parties moved the district court for entry of a
certificate pursuant to Rule <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X144L48003?jcsearch=Fed.%20R.%20Civ.%20P.%2054(b)&amp;summary=yes#jcite">54</a>(b) of the Federal Rules of
Civil Procedure, which would allow the disposed issues to be
immediately appealed. The district court granted the motion and
entered the Rule 54(b) certificate. We have permitted parties
to establish appellate jurisdiction with a nunc-pro-tunc
Rule 54(b) certificate. <i>Storage Tech. Corp. v. Cisco Sys.,</i>
<i>Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X6CODM?jcsearch=329%20f%203d%20823&amp;summary=yes#jcite">329 F.3d 823</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X6CODM?jcsearch=329%20f%203d%20823&amp;summary=yes#jcite">829-30</a> (Fed. Cir. 2003); <i>State</i>
<i>Contracting &amp; Eng'g Corp. v. Fla.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X511AG?jcsearch=258%20f%203d%201329&amp;summary=yes#jcite">258 F.3d 1329</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X511AG?jcsearch=258%20f%203d%201329&amp;summary=yes#jcite">1334-35</a> (Fed. Cir. 2001). While the parties should have moved
for entry of a Rule 54(b) certificate before filing their
appeals, the late-filed certificate is sufficient to establish
appellate jurisdiction under our precedent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                  VII.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We reverse and vacate the district court's invalidity judgment
and affirm its best mode ruling. We dismiss as premature
Mylan's appeal from the district court's entry of the
injunction. To allow the district court an opportunity to
assess the propriety of a preliminary injunction pending
further proceedings, the injunction will remain in place for
forty-five days post-mandate, or until further order of the
district court, whichever occurs sooner.
<span CLASS="page_no" data-cite="102 uspq 2d 1781" data-cite-type="ReporterOfDecisions" data-cite-pageno="1781" data-primary-citation="102 U.S.P.Q.2d 1760">[**1781]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>AFFIRMED IN PART, REVERSED IN PART, VACATED IN PART,</b>
<b>DISMISSED IN PART</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> The district court also relied upon the testimony of
another defense expert, Dr. Courtney Fletcher, to find that the
Tmax can be calculated when the other parameters of
the model are known. Because Cephalon is correct that Dr.
Fletcher was not qualified to testify to that point, any
reliance on Dr. Fletcher for this proposition was clear error.
Indeed, the district court seemed to concede this point when
responding to the errors that Cephalon identified in the
court's trial opinion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> While it might appear to a layperson that 129.5% is
"about" 125%, expert testimony is necessary to establish how a
person having ordinary skill in the art would perceive those
figures. We have no way of knowing the importance of even small
differences in these percentages in the absence of some
evidence in the record addressing that point. <i>See</i>
<i>Ortho-McNeil Pharm., Inc. v. Caraco Pharm. Labs., Inc.</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X166O42003?jcsearch=476%20f%203d%201321&amp;summary=yes#jcite">476 F.3d 1321</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X166O42003?jcsearch=476%20f%203d%201321&amp;summary=yes#jcite">1326</a> (Fed. Cir. 2007) ("The use of the word
"about." avoids a strict numerical boundary to the specified
parameter. Its range must be interpreted in its technological
and stylistic context." (quoting <i>Pall Corp. v. Micron</i>
<i>Separations, Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5379J?jcsearch=66%20f%203d%201211&amp;summary=yes#jcite">66 F.3d 1211</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5379J?jcsearch=66%20f%203d%201211&amp;summary=yes#jcite">1217</a> (Fed. Cir.
1995))).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> <i>See, e.g., Innovention Toys, L.L.C. v. MGA Entm't,</i>
<i>Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1F5448003?jcsearch=637%20f%203d%201314&amp;summary=yes#jcite">637 F.3d 1314</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1F5448003?jcsearch=637%20f%203d%201314&amp;summary=yes#jcite">1323</a> (Fed. Cir. 2011) ("[S]hould the
district court conclude [on remand] that [defendant] has made
out a <i>prima facie</i> case of obviousness based on the
[prior art], the court must then determine whether [plaintiffs]
secondary considerations overcome [defendant's] <i>prima</i>
<i>facie</i> case"); <i>Transocean Offshore Deepwater Drilling,</i>
<i>Inc. v. Maersk Contractors USA, Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1E2RA2003?jcsearch=617%20f%203d%201296&amp;summary=yes#jcite">617 F.3d 1296</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1E2RA2003?jcsearch=617%20f%203d%201296&amp;summary=yes#jcite">1305</a>
(Fed. Cir. 2010) ("If all of the factual disputes regarding the
objective evidence resolve in favor of [plaintiff], it has
presented a strong basis for rebutting the <i>prima facie</i>
case [of obviousness]."); <i>Muniauction, Inc. v. Thomson</i>
<i>Corp.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X197TO0003?jcsearch=532%20f%203d%201318&amp;summary=yes#jcite">532 F.3d 1318</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X197TO0003?jcsearch=532%20f%203d%201318&amp;summary=yes#jcite">1327</a> (Fed. Cir. 2008) ("Under the
foregoing analysis, we conclude that [defendant] has clearly
and convincingly established a prima facie case that claims 1
and 31 of the &prime;<cite>099 patent</cite> are obvious as a matter of law.
Accordingly, we turn to [plaintiff's] attempt to rebut this
prima facie case with secondary considerations of
nonobviousness."); <i>Eli Lilly &amp; Co. v. Zenith Gold-line</i>
<i>Pharms., Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X164AGG003?jcsearch=471%20f%203d%201369&amp;summary=yes#jcite">471 F.3d 1369</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X164AGG003?jcsearch=471%20f%203d%201369&amp;summary=yes#jcite">1380</a> (Fed. Cir. 2006)
("[Plaintiff] overcame any prima facie case of obviousness . . .
[because it] proved extensive secondary considerations to
rebut obviousness"); <i>Ormco Corp. v. Align Tech., Inc.</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X15JPH8003?jcsearch=463%20f%203d%201299&amp;summary=yes#jcite">463 F.3d 1299</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X15JPH8003?jcsearch=463%20f%203d%201299&amp;summary=yes#jcite">1311</a> (Fed. Cir. 2006) ("A nonmovant may rebut a
prima facie showing of obviousness with objective indicia of
nonobviousness."); <i>Iron Grip Barbell Co. v. USA Sports,</i>
<i>Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XGA31H?jcsearch=392%20f%203d%201317&amp;summary=yes#jcite">392 F.3d 1317</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XGA31H?jcsearch=392%20f%203d%201317&amp;summary=yes#jcite">1325</a> (Fed. Cir. 2004) ("[W]e conclude
that there is no objective evidence to rebut the strong showing
of obviousness based on the prior art."); and <i>WMS Gaming,</i>
<i>Inc. v. Int'l Game Tech.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X36AV9?jcsearch=184%20f%203d%201339&amp;summary=yes#jcite">184 F.3d 1339</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X36AV9?jcsearch=184%20f%203d%201339&amp;summary=yes#jcite">1359</a>
(Fed. Cir. 1999) ("The objective evidence of non-obviousness may
be used to rebut a prima facie case of obvious-ness based on
prior art references.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> The Court's treatment of the burden of persuasion in the
obviousness context markedly differs from its treatment of the
burden of persuasion in other contexts, such as employment
discrimination claims under Title VII of the Civil Rights Act
of 1964. In <i>McDonnell Douglas Corp. v. Green</i>, the
Court established the well-known formal, three-part
burden-shifting framework that a plaintiff must satisfy to
prove a discrimination claim with cir cumstantial evidence.
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C8GA?jcsearch=411%20us%20792&amp;summary=yes#jcite">411 U.S. 792</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C8GA?jcsearch=93%20supreme%20court%201817&amp;summary=yes#jcite">93 S.Ct. 1817</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5C8GA?jcsearch=36%20l%20ed%202d%20668&amp;summary=yes#jcite">36 L.Ed.2d 668</a> (1973). Several
differences are apparent between the Court's burden-shifting
framework under <i>McDonnell Douglas</i> and its treatment of
the burden of proof with respect to obviousness. First, the
term "prima facie," as used in the <i>McDonnell Douglas</i>
context, means "the establishment of a legally mandatory,
rebuttable presumption," as opposed to "the plaintiff's burden
of producing enough evidence to permit the trier of fact to
infer the fact at issue." <i>Tex. Dep't of Cmty. Affairs v.</i>
<i>Burdine</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CA2Q?jcsearch=450%20us%20248&amp;summary=yes#jcite">450 U.S. 248</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CA2Q?jcsearch=450%20us%20248&amp;summary=yes#jcite">254</a> n. 7, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CA2Q?jcsearch=101%20supreme%20court%201089&amp;summary=yes#jcite">101 S.Ct. 1089</a>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CA2Q?jcsearch=67%20l%20ed%202d%20207&amp;summary=yes#jcite">67 L.Ed.2d 207</a> (1981). As discussed above, the Court has never
spoken in terms of a legally rebuttable presumption with
respect to obviousness. Second, the Court's rationale for
fashioning a formal burden-shifting framework in employment
discrimination cases is to facilitate inquiry into an
employer's intent: "the allocation of burdens and the creation
of a presumption by the establishment of a prima facie case is
intended progressively to sharpen the inquiry into the elusive
factual question of intentional discrimination."
<i>Burdine</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CA2Q?jcsearch=450%20us%20248&amp;summary=yes#jcite">450 U.S. at 256</a> n. 8, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X5CA2Q?jcsearch=101%20supreme%20court%201089&amp;summary=yes#jcite">101 S.Ct. 1089</a>. While
the obviousness inquiry undoubtedly demands precision, the
Court has never identified a problem in its application such
that "sharpening" by way of a burden-shifting scheme is
necessary.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> It is true that, in most cases, it is a patentee who
chooses to offer proof of objective considerations as evidence
of nonobviousness. It is also true that district courts will
often impose a discovery obligation on patentees to be the
first to produce evidence relating to objective considerations.
And, it is true that district courts also often require
patentees to present their objective evidence during their case
in chief to make an efficient use of time and resources during
trial, relying on their authority under Federal Rule of
Evidence <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X135KM4003?jcsearch=Federal%20Rule%20of%20Evidence%20611(a)&amp;summary=yes#jcite">611</a>(a) to structure the presentation of evidence.
Those realities do not change the fact that the party
challenging validity bears the burden of persuasion throughout
the litigation. 141, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">131 S.Ct. at 2245</a> &amp;
n. 4.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> To be sure, courts must exercise care in assessing
proffered evidence of objective considerations, giving such
evidence weight only where the objective indicia are
"attributable to the inventive characteristics of the discovery
as claimed in the patent." <i>See</i> Rochelle Cooper
Dreyfuss, <i>The Federal Circuit: A Case Study in Specialized</i>
<i>Courts</i>, 64 N.Y.U. L. Rev. 1. 10 (1989) (noting that this
court has imposed such a "nexus" requirement on the objective
considerations). <i>See also Ormco Corp. v. Align Tech.,</i>
<i>Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X15JPH8003?jcsearch=463%20f%203d%201299&amp;summary=yes#jcite">463 F.3d 1299</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X15JPH8003?jcsearch=463%20f%203d%201299&amp;summary=yes#jcite">1311-12</a> (Fed. Cir. 2006) (noting that a
nexus must exist between a product's commercial success and the
claimed invention).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> It appears that the language discussing a two-part,
burden-shifting inquiry may have originated in and been
borrowed from the test employed in appeals from the Board of
Patent Appeals and Interferences. In <i>Iron Grip</i>
<i>Bar-bell</i>, for example, we stated that a "presumption of
obviousness" that exists when a claimed invention falls within
a range disclosed in the prior art could be "rebutted if it can
be shown: (1) That the prior art taught away from the claimed
invention . . . or (2) that there are new and unexpected
results." <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XGA31H?jcsearch=392%20f%203d%201317&amp;summary=yes#jcite">392 F.3d at 1322</a>. For that proposition, we cited
<i>In re Geisler</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3BBCD?jcsearch=116%20f%203d%201465&amp;summary=yes#jcite">116 F.3d 1465</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3BBCD?jcsearch=116%20f%203d%201465&amp;summary=yes#jcite">1471</a> (Fed. Cir. 1997),
and <i>In re Woodruff</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X32LCT?jcsearch=919%20f%202d%201575&amp;summary=yes#jcite">919 F.2d 1575</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X32LCT?jcsearch=919%20f%202d%201575&amp;summary=yes#jcite">1578</a>
(Fed. Cir. 1990). Both of those cases were appeals from
obviousness rejections during prosecution. <i>In re</i>
<i>Geisler</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3BBCD?jcsearch=116%20f%203d%201465&amp;summary=yes#jcite">116 F.3d at 1467</a>; <i>In re Woodruff</i>,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X32LCT?jcsearch=919%20f%202d%201575&amp;summary=yes#jcite">919 F.2d at 1575</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Unlike in district court litigation, a burden-shifting
framework makes sense in the prosecution context. The prima
facie case furnishes a "procedural tool of patent examination,
allocating the burdens of going forward as between examiner and
applicant." <i>In re Oetiker</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3K0EK?jcsearch=977%20f%202d%201443&amp;summary=yes#jcite">977 F.2d 1443</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3K0EK?jcsearch=977%20f%202d%201443&amp;summary=yes#jcite">1445</a>
(Fed. Cir. 1992). During prosecution, a patent applicant, as a
practical matter, may not have the opportunity to present
objective evidence unless and until an examiner reviews the
application and issues an obviousness rejection. This is
because "the examiner bears the initial burden, on review of
the prior art or on any other ground, of presenting a prima
facie case of unpatentability. If that burden is met, the
burden of coming forward with evidence or argument shifts to
the applicant." <i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3K0EK?jcsearch=977%20F.2d%201443&amp;summary=yes#jcite">Id</a>.</i> Courts should not apply the
burden-shifting frame-work for patentability appeals to
invalidity determinations appealed from a district court,
however, because the prosecution and litigation contexts are
distinct.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the prosecution context, not only are the decision maker and
the patent holder the only two parties involved, but that
decision maker &mdash; the examiner &mdash; is required to
determine patentability by a preponderance of the evidence.
<i><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X3K0EK?jcsearch=977%20F.2d%201443&amp;summary=yes#jcite">Id</a>.</i> Evidence of objective considerations also may not
be available until years after an application is filed, and
until long after the examiner first considers the prior
art. Litigation differs significantly from the examination process.
First, in the litigation context, validity, rather than
patentability, is the issue. The challenged patent enjoys a
presumption of validity, and the challenger must convince a
third-party decision maker of the patent's invalidity by clear
and convincing evidence, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/XEJ050003?jcsearch=35%20usc%20282&amp;summary=yes#jcite">35 U.S.C. &sect; 282</a>: 141,
<a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">131 S.Ct. at 2242</a>. And, in litigation, all relevant evidence is
presented to the fact finder in a single proceeding. There is
simply no practical need to impose a burden-shifting framework
in litigation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> We find no error in the district court's conclusion that
Cephalon failed to offer adequate proof of reduced sedation
through its formulation and, thus, could not rely on unexpected
results to support its contention that Mylan and Par failed to
prove obviousness by clear and convincing evidence. While we
question the trial court's interpretation of Eurand's evidence
of commercial success, moreover, we cannot find clear error
therein. That these objective criteria do not strongly support
a finding of nonobviousness does not affect our conclusions,
however. On both points, we find the evidence to be neutral;
while they do not support a finding of nonobviousness, they add
little to Mylan and Par's claim of obviousness. While evidence
of reduced sedation may not have been strong, the patents in
suit do not claim that benefit; they claim only therapeutic
effectiveness. And, while Amrix's commercial success may be
slow in coming, it is clear its success is increasing, as its
benefits &mdash; particularly greater compliance &mdash; become
known.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn900" name="fn900">[fn9]</a></span> Cephalon also claims that Merck and Schering-Plough tried
but failed to develop an extended-release formulation. The
evidence of Merck's and Schering-Plough's alleged failures,
however, is weak, and the district court did not clearly err in
disregarding it.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1000" name="fn1000">[fn10]</a></span> The parties have not cited any cases in which the
presence or absence of a known <b>PK/PD</b> relationship was
determinative. Indeed, in other cases, it appears that the
parties and the court assumed bioequivalence would produce a
therapeutically effective result. <i>See Abbott Labs. v. Andrx</i>
<i>Pharms., Inc.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1592FS003?jcsearch=452%20f%203d%201331&amp;summary=yes#jcite">452 F.3d 1331</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1592FS003?jcsearch=452%20f%203d%201331&amp;summary=yes#jcite">1340-43</a> (Fed. Cir. 2006)
(finding a substantial question of validity on a preliminary
injunction motion where the prior art disclosed substantially
bioequivalent PK values, but failing to address whether
bioequivalent PK values would produce a therapeutically
effective result); <i>Adams Respiratory Therapeutics, Inc. v.</i>
<i>Perrigo Co.</i>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1DTP52003?jcsearch=616%20f%203d%201283&amp;summary=yes#jcite">616 F.3d 1283</a>, <a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1DTP52003?jcsearch=616%20f%203d%201283&amp;summary=yes#jcite">1289</a> (Fed. Cir. 2010)
(reversing a district court's grant of summary judgment because
a fact finder could reasonably find infringement based on the
accused <b>ANDA</b> product's having a Cmax
equivalent to that of a standard immediate-release
product).
</p></div>
<!--BBLS DD 1699955998723-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HF6KC003/history">Direct History (15)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HF6KC003/analysis">Case Analysis (57)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HF6KC003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
57
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed (In Part), Judgment Reversed (In Part), Judgment Vacated (In Part), Appeal Dismissed (In Part)</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Pharmaceutical Manufacturing</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1Q6LJUKSB82">11-01399 (Fed. Cir.)</a></div><div class='facetItemLabel'><a href="/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/document/X1Q6LK8MNHO2">11-01409 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Civil Procedure</div><div class='facetItemLabel'>Damages &amp; Remedies</div><div class='facetItemLabel'>Patent Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/8aa6afcb6c93e1fd566e4a7344efbc84/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "8aa6afcb6c93e1fd566e4a7344efbc84";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY6946ad&previousPageId=&previousActivityInstanceId=ENTITY4403f0&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:44:17-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1HF6KC003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY4403f0&previousPageId=&previousActivityInstanceId=ENTITYc69a32&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:44:12-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1HF6KC003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1HF6KC003";
$('#page_loader').show().spin();
JUDGE_IDS=["1850676","3057465","4283465"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
